

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

**Magnetothermal genetic deep brain stimulation of
motor behaviors in awake, freely moving mice**

*Rahul Munshi^{1,#}, Shahnaz M. Qadri^{1,#}, Qian Zhang², Idoia Castellanos Rubio¹,
Pablo del Pino³, and Arnd Pralle^{1*}*

¹Department of Physics, University at Buffalo, Buffalo, NY 14260, USA

²Department of Physics, Philipps University Marburg, Marburg, Germany

³CIC biomaGUNE, Paseo Miramón nº 182, 20009 San Sebastian, Spain

Co-first authors

* Corresponding author: Arnd Pralle: apralle@buffalo.edu

26 **ABSTRACT**

27 Establishing how neurocircuit activation causes particular behaviors requires
28 modulating the activity of specific neurons. Here, we demonstrate that magnetothermal
29 genetic stimulation provides tetherless deep brain activation sufficient to evoke motor
30 behavior in awake mice. The approach uses alternating magnetic fields to heat
31 superparamagnetic nanoparticles on the neuronal membrane. Neurons heat-sensitized
32 by expressing TRPV1 are activated with magnetic field application. Magnetothermal
33 genetic stimulation in the motor cortex evoked ambulation, deep brain stimulation in the
34 striatum caused rotation around the body-axis, and stimulation near the ridge between
35 ventral and dorsal striatum caused freezing-of-gait. The duration of the behavior
36 correlated tightly with field application. This approach provides genetically and spatially
37 targetable, repeatable and temporarily precise activation of deep-brain circuits without
38 need for surgical implantation of any device.

39

40 **MAIN TEXT**

41 **Introduction**

42 Identifying neural circuitry controlling specific behaviors requires the ability to
43 communicate with specific neurons in the brains of awake, freely moving animals. The
44 most established interface is electrodes implanted in the brain. They provide rapid
45 neuronal stimulation and recording, however, at the cost of being invasive and with
46 limited spatial and cell type targeting. Optogenetics, visible light-based stimulation of
47 neurons genetically engineered to express light gated channels and ion pumps,
48 provides genetic targeting of specific cell types in combination with rapid stimulation
49 (Banghart et al., 2004; Boyden et al., 2005). The method quickly gained popularity and
50 has been used in various animal models to study brain circuits associated with for
51 Parkinson's Disease (Gradinaru et al., 2009; Kravitz et al., 2010), addictive behavior
52 (Chen et al., 2013; Stefanik et al., 2013), depression (Nieh et al., 2013; Zhu et al., 2016)
53 and anxiety (Tye et al., 2011). However, optogenetics requires permanent brain

54 implants to guide the light into the brain, and typically, an optical fiber tethering the
55 animal to the light source. A third approach, pharmacological neuromodulation using
56 Designer GPCRs Exclusively Activated by Designer Drugs (DREADDs), provides a
57 tetherless alternative to optogenetics, but generates a much slower response, ranging
58 from tens of minutes to hours, as the drug must diffuse to the location of action
59 (Armbruster et al., 2007; Urban and Roth, 2015). The ideal experimental approach to
60 deep brain stimulation would combine minimal invasiveness - to avoid perturbing the
61 behavior, sufficient speed - to permit real-time response, and cell-specific targeting.

62 Magnetic field based stimulation has considerable potential to provide fast,
63 tetherless, and implant free deep brain stimulation because magnetic fields are
64 minimally scattered, minimally absorbed by tissue, and travel freely through space
65 (Walsh and Cowey, 2000). These characteristics of magnetothermal stimulation
66 simplifies a range of experimental assays, which are challenging to perform using
67 current techniques, and permit new types of experiments: The absence of tethers will
68 permit novel social behavioral assays in a group of animals freely interacting in an
69 arena, while only a subgroup of them gets stimulated. As magnetic stimulation only
70 occurs when the animal resides within the magnetic field, the field geometry can be
71 adapted to coincide with another signal for conditional place preference or feeding
72 assays. Similarly, magnetically stimulating multiple sites in one brain to study network
73 connectivity requires only multiple injections of solutions, possibly along a shared
74 injection path, as opposed to of multiple cannula implantations. Furthermore, the
75 absence of any physical connection from brain to skull minimizes tissue damage and
76 immune response (Chen et al., 2015). Lastly, assays using animals easily startled by
77 the flashes of visible light used in optogenetics, such as Zebrafish, would benefit from
78 magnetic stimulation. Therefore, a reliable magnetic field stimulation method would not
79 only simplify experiments currently performed using existing techniques, but enable a
80 series of novel assays.

81 The challenge in implementing magnetic stimulation has been to develop a
82 transducer capable of harnessing the energy of the magnetic field and translating it into
83 a robust biological signal with high temporal and spatial specificity. Magnetic fields only

84 interact with magnetic dipoles. The overall magnetic dipole of a particle is caused by the
85 particle's intrinsic magnetic moment, which results from the orientation of a large
86 number of spins of the ions making up the nanoparticle. The spins in a ferromagnet
87 interact strongly, causing their parallel alignment to persist over time, and creating a
88 permanent magnetic moment. In ferromagnetic particles, the magnetic moment is fixed
89 to the particle crystal structure, causing a net magnetic dipole of the particle, which
90 interacts strongly with external magnetic fields. However, the permanent dipoles of
91 individual particles interact also in absence of an external field, causing aggregation of
92 particles, rendering them unsuitable for neurostimulation.

93 In very small particles made from materials that are ferromagnetic in bulk, the spins
94 interact, but at room temperature the direction of their magnetic moment relative to the
95 particle fluctuates rapidly (Brown, Jr, 1963). After an external magnetic field aligns the
96 moments, this alignment persists for a brief moment of time to permit the interaction.
97 Such particles are called superparamagnetic (Bean and Livingston, 1959). They are the
98 preferred transducer for magnetic biostimulation (Hofmann-Amttenbrink et al., 2009;
99 Pankhurst et al., 2009). Superparamagnetic particles can be used as a transducer of
100 magnetic field energy exploiting two different mechanisms: In a strong external DC field,
101 the induced magnetic dipoles in neighboring NPs interact sufficiently strongly to
102 aggregate the NPs and a field gradient exerts a small force (Mannix et al., 2008).
103 Alternatively, our group showed that applying an alternating magnetic field (AMF) to
104 superparamagnetic nanoparticles may be used to locally generate heat, which then
105 activates nearby temperature sensitive TRPV1 channels (Huang et al., 2010). This later
106 approach, when used to stimulate TRPV1⁺ neurons, is referred to as "magnetothermal
107 genetics"(Chen et al., 2015; Huang et al., 2010; Stanley et al., 2012).

108 Activating a channel requires overcoming an energy barrier slightly larger than the
109 thermal fluctuation energy ($E_{thermal} = k_B T \sim 4 \cdot 10^{-21} J$ at 37°C, with Boltzmann constant k_B).
110 The maximally delivered energy per transducer particle depends on the mechanism of
111 interaction with the magnetic field. In the case of dipole-dipole interaction of two NPs
112 with magnetic dipole m and a distance r apart, their interaction energy is
113 $E_{dipole} \sim \mu_0 m^2 / 4\pi r^3$ (μ_0 being the vacuum permeability). In a 0.1 T external field, the

114 magnetic dipole of two core-shell NPs used in this study is strong enough that their
115 E_{dipole} is larger than the thermal energy as soon as they are closer than 22 nm (García-
116 Prieto et al., 2016; Q. Zhang et al., 2015) (Figure 1 - figure supplement 4A and B).
117 However, for horse ferritin the magnetic dipole at 0.1 T per particle is so weak that the
118 dipole interaction energy is a lot smaller than the thermal energy even if the ferritin
119 molecules were touching each other (García-Prieto et al., 2016; Q. Zhang et al., 2015)
120 (Figure 1 - figure supplement 4B).

121 In magnetothermal stimulation, the transducer converts the energy of the external
122 alternating magnetic field into heat. This process depends on the frequency f and field
123 strength H of the external magnetic field, the time τ over which thermal fluctuations
124 randomize the orientation of the moments in the particle, the particle volume and
125 magnetization. The synthesized nanoparticles used in this study, heat 450 W/g at 500
126 kHz and 15 kA/m, while horse ferritin does not heat in the same AMF (Figure 1 - figure
127 supplement 4C). Even if increasing the frequency driving ferritin to 50 MHz and 0.15
128 kA/m horse ferritin heats less than 1 W/g. In this comparison, the product $H \cdot f$ is left
129 constant as it is a measure for background effects in tissue (Atkinson et al., 1984; Chen
130 et al., 2015). Hence, transducers coupling either via dipole-dipole or magnetothermal
131 mechanism, deliver sufficient energy if using consisting of synthesized
132 superparamagnetic NPs. This is in contrast to the unclear physics of ferritin based
133 magnetogenetics (Meister, 2016; Stanley et al., 2015, 2012; Wheeler et al., 2016).

134 In magnetothermal genetic stimulation, the heat needs to be delivered to the
135 TRPV1 channel efficiently, avoiding excess heat loss to the surrounding buffer fluid.
136 Classically, magnetic nanoparticle-based hyperthermia heating uses a dense
137 suspension of nanoparticles, a ferrofluid, in which the neighboring MNPs screen the
138 cooling. An isolated MNP delivers only a few femtowatts of heat, which dissipates
139 rapidly into the volume of water. In a two-dimensional dense array of MNPs on the
140 membrane, the neighboring MNPs screen the lateral cooling, leaving only the direction
141 normal to the membrane for heat dissipation. Membrane bound MNPs deliver sufficient
142 power to raise the temperature in a thin sheet along the membrane (Huang et al., 2010).

143 Therefore, we aimed to use AMF heating of membrane targeted MNP to evoke behavior
144 in awake animals.

145 Here, we report the first robust and repeated magnetothermal genetic activation of
146 motor behavior in awake, freely moving mice using magnetic nanoparticles (MNPs),
147 attached to the plasma membrane of temperature sensitized TRPV1⁺ neurons, deep
148 inside the brain. We demonstrate successful magnetothermal activation of three
149 separate brain regions, motor cortex, dorsal striatum and ridge between dorsal and
150 ventral striatum. All three have been previously activated either optogenetically
151 (Gradinaru et al., 2007; Kravitz et al., 2010) or chemogenetically (Arenkiel et al., 2008).
152 We observed the same behavioral responses as had been reported resulting from
153 optogenetic or chemogenetic neurostimulation in those areas. We were able to achieve
154 successful neurostimulation in-vivo without raising the overall tissue temperature by
155 binding MNPs to the neuronal membrane. This magnetothermal method does not
156 require any fixed implants or tethers, thereby permitting repeatable stimulation with real
157 time response monitoring and recording in awake freely moving mice capabilities.

158

159 **Results**

160 **Principles of magnetothermal genetic neurostimulation**

161 To achieve fast and robust neuronal stimulation in awake, freely behaving mice, we
162 depolarized heat-sensitized (TRPV1⁺) neurons via magnetic field induced heating of
163 superparamagnetic MNPs (Figure 1A, B, F). The MNPs were targeted to the neuronal
164 membrane via an A2B5 antibody specific to neuronal glycosylated membrane proteins.
165 This approach provided specific and dense labeling of neuronal membranes (Figure
166 1E), minimizing the amount of MNPs required for activation.

167 **Development and synthesis of an optimal Magnetothermal transducer**

168 An effective magnetothermal transducer must convert the alternating magnetic field
169 energy efficiently into heat, be targetable to specific cells and sufficiently small to easily
170 diffuse between the neurons in the brain (<30 nm) (Thorne and Nicholson, 2006).
171 Exchange-coupled core-shell MNPs combining soft and hard magnetic materials

172 (Cobalt Oxide and Manganese oxide) in a core-shell geometry, permit independent
173 optimization of the MNP's size and magnetic properties (Lee et al., 2011; Zhang et al.,
174 2015). Thus, these MNPs can be tuned to heat efficiently at magnetic field frequencies,
175 known to safely penetrate tissue (<1 MHz) (Young et al., 1980), while maintaining a
176 diameter of less than 30 nm.

177 We synthesized MNPs with an 8.0 ± 1.0 nm Co-ferrite core surrounded by a 2.25
178 nm Mn-ferrite shell. To confer colloidal stability in physiological buffers these MNPs
179 were then encapsulated in the polymer PMA (dodecyl-*grafted*-poly-(isobutylene-*alt*-
180 maleic-anhydride) (Lin et al., 2008). The PMA coating added 5.4 ± 1.4 nm to the MNP
181 diameter (Figure 1D). We carefully analyzed the experimental magnetic and heating
182 properties of these MNPs and found the results to be well described by the theory of
183 superparamagnetic NPs (Zhang et al., 2015). The efficiency of particular MNPs in
184 converting AMF power to heat is measured and quantified as specific loss in power
185 (SLP) in W/g. The MNPs used in this study have a SLP of 733.3 ± 2.8 W/g at 37.0 kA/m
186 and 412.5 kHz, close to the theoretical maximum for particles of this size (Q. Zhang et
187 al., 2015).

188 To target the MNPs specifically to neurons, we functionalized them with NeutrAvidin
189 which then binds biotinylated antibodies. We used either antibodies against
190 endogenous neuronal surface markers, such as anti-CD56 (Thy-1), anti-CD90 (NCAM)
191 or anti-A2B5, or against a fluorescent protein tag. The later allowed genetic targeting of
192 specific cells, transiently expressing a surface protein with an extracellular GFP or
193 mCherry (Figure 1 - figure supplement 2A and B).

194 The local temperature rise in the vicinity of the nanoparticles was measured by
195 fluorescence intensity changes of a Dylight 550 fluorophore integrated in the
196 NeutrAvidin coating. The fluorescence intensities of molecular fluorophores are
197 sufficiently temperature dependent to provide a molecular scale thermometer (Huang et
198 al., 2010). We found that the fluorescence intensity of DyLight 550 decreased by 2.2%
199 per degree temperature rise (Figure 1 - figure supplement 3).

200 **Membrane bound Nanoparticles produced efficient, well localized heating**

201 To open a sufficient number of TPRV1 channels to affect neuronal firing, the cell
202 surface temperature needs to rise only a few degrees above the physiological
203 temperature (Huang et al., 2010, Chen et al., 2015). First, we determined the efficacy of
204 AMF driven heating of MNPs in suspension, aka ferrofluid, and then separately of
205 membrane bound MNPs, using identical experimental conditions and AMF (Figure 2).
206 Bath temperature was measured continuously using an immersed fiber optic
207 thermometer (Figure 2A), while the membrane temperature was measured using the
208 fluorescence intensity of DyLight 550 integrated in the NeutrAvidin coating of the
209 membrane bound MNPs (Figure 2B). The AMF (22.4 kA/m at 412.5 kHz) was generated
210 in a custom built, water-cooled coil, surrounding the sample dish, which was mounted
211 on an inverted microscope.

212 In the MNP suspension sample, the entire bath temperature (along with the cells)
213 rose by two degrees (Figure 2C). Following a seven second AMF heating, the MNP
214 suspension required more than one minute to cool back the initial temperature.
215 Conversely, when the MNPs were bound to the cell membrane, only the membrane,
216 and not the bath, was heated by several degrees (Figure 2D). After removing the AMF,
217 the membrane temperature returned to the initial value within a few seconds. Hence,
218 using membrane bound MNPs provides a temporal precision of few seconds for
219 terminating the magnetothermal neurostimulation.

220 The rates of temperature increase depend on the concentration of MNPs. For
221 various volume concentrations of MNPs we measured rates from 0.1 to 0.5 °C/s (Figure
222 2E). For membrane bound MNPs, the rates were 0.1 to 1.0 °C/s, depending on the area
223 density of MNP (Figure 2F). Plotting the heating rate as function of MNP concentration
224 collapses these measurements. For suspension heating, the heating rate depends
225 linearly on the MNP concentration and is fit to $5.8 \times 10^{-4} \pm 1.9 \times 10^{-6} \text{ } ^\circ\text{C} \cdot \mu\text{m}^3/\text{s}$ (Figure 2G).
226 Hence, the heating power per MNP is $2.55 \pm 0.94 \text{ fW/particle}$, consistent with the
227 prediction from magnetic measurements, 3.34 fW/particle (Q. Zhang et al., 2015). In the
228 membrane bound case, the graph of the heating rate versus MNP area density is fit to
229 $1.1 \times 10^{-3} \pm 6.7 \times 10^{-5} \text{ } ^\circ\text{C} \cdot \mu\text{m}^2/\text{s}$ (Figure 2H). Comparing the fit obtained for the membrane
230 heating to the suspension heating shows that the volume of water heated in the

231 membrane case corresponds to a 0.5mm thick slab of MNP suspension. In reality the
232 temperature away from the membrane drops inversely with the distance from the
233 membrane (Baffou et al., 2013). Figures 2I and 2J visualize MNP spacing for membrane
234 and suspension cases, assuming homogenous MNP distribution.

235 To determine a lower bound for the field strength AMF required for local membrane
236 heating, we compared the membrane temperature increase in HEK cells decorated with
237 MNPs at two different field strength, 12 kA/m and 30 kA/m (both at 412 kHz). A 30s
238 application of the weaker AMF heated the membrane as much as a 5s application of the
239 stronger AMF (Figure 2 - supplement 1). However, at 12 kA/m AMF, once the local
240 temperature has rising more than $2\text{ }^{\circ}\text{C}$ above the environment, cooling to the
241 environment becomes comparable to the heating. Hence, even during longer AMF
242 applications the maximal local temperature increase will remain in a safe range for cells.

243 Overall, we found that for membrane bound MNP, the duration of AMF to achieve
244 the two-degree rise necessary to activate TRPV1 channels varies between 2.1 s and
245 4.2 s (Figure 2F). The amount of MNPs required for similar heating rates in suspension
246 heating is a few orders higher, 20 - 30 mg/ml (Figure 2E – H).

247 **Thermal activation of TRPV1⁺ hippocampal neurons**

248 To measure the response of TRPV1⁺ hippocampal neurons to thermal stimulation,
249 we used the fast genetically encoded calcium indicator GCaMP6f (Chen et al., 2015;
250 Grewe et al., 2010), and deconvolved the Ca^{2+} transients to uncover the underlying
251 spike train (Figure 3 - figure supplement 1). First, we investigated the spontaneous firing
252 rate of 10-day old TRPV1⁺ hippocampal neurons across a range of physiologically
253 relevant bath temperatures. From 32°C to 36°C , the Calcium spiking rate was
254 temperature independent. As bath temperature was increased from 37°C to 39°C ,
255 spontaneous activity of TRPV1⁺ neurons increased from 1.5 ± 1.2 action potentials
256 (APs) per 5 seconds to 13 ± 3 APs in the same period. At 39°C , only about 15-20% of
257 rat TRPV1 channels open (Grandl et al., 2010), but the resulting Calcium influx is
258 sufficient to trigger neuronal activity because TRPV1 has an about 1,000-fold higher
259 single channel conductance than ChR2 (Lórenz-Fonfría and Heberle, 2014; Studer and
260 McNaughton, 2010). In control neurons, without TRPV1, we observed a slight decrease
261 of the spiking rate, to 1 ± 1 APs per 5 seconds (Figure 3A). Detailed analysis of single

262 calcium transients in the absence of TRPV1, and with TRPV1 at channel activating
263 temperatures showed, that, within the resolution of GCaMP6f based calcium imaging,
264 TRPV1 activity does not change the shape of the calcium transient and the underlying
265 AP (Figure 3 - figure supplement 1). Therefore, expressing of TRPV1 in hippocampal
266 neurons renders their firing rate highly heat-sensitive without disrupting natural function.

267 **Membrane localized MNP heating stimulates cultured hippocampal neurons**

268 To measure the MNP heating evoked stimulation, we transfected cultured
269 hippocampal neurons with TRPV1 and GCaMP6f, then decorated the plasma
270 membrane with MNPs. The red fluorescence of the DyLight550 labeled MNPs was
271 detected all along the neuronal membrane, indicating good surface labeling (Figure 1E).

272 When exposed to an AMF (22.4 kA/m at 412.5 kHz, 5s), MNP decorated
273 TRPV1⁺ neurons showed increased spiking, measured as calcium transients (Figure 1F,
274 3B). The spike train of each neuron was derived from the recorded Calcium transients
275 by convolving an estimated spike train with the recorded GCaMP6f calcium signal of a
276 single Action Potential; then calculating the residual between the measured and the
277 computed calcium trace; and adjusting the estimated spike train to minimize the residual
278 (see Methods and Figure 3 - figure supplement 1) (Yaksi and Friedrich,
279 2006). Compared to basal activity (1.8 ± 0.6 APs) during five seconds before AMF
280 application, the spiking increased significantly to 4.5 ± 1.2 APs during the 5 s AMF ($p =$
281 0.0028 , unpaired T-test), and 12.1 ± 2.0 APs in the five seconds after the AMF was
282 removed ($p = 0.0002$, unpaired T-test) ($n = 13$ cells, 3 cultures) (Figure 3D, Figure 3-
283 figure supplement 2). During the AMF application, the membrane temperature of MNP
284 decorated TRPV1⁺ neurons increased by 2°C , as measured by the DyLight550
285 fluorescence (Figure 3C). The stimulation is very reproducible with 87.5% of the cells
286 responding to second stimulation, following 5 minutes after the first.

287 **Latency and consistency of magnetothermal stimulation**

288 We analyzed the consistency of activation, increase in firing rate and number of
289 active cells, as well as the activation latency. Figure 3E shows the activation latency,
290 the temporal delay between the start of field application and the first spiking event, for
291 all recorded stimulations (79 neurons, 6 cultures, various duration of AMF). 87 % of

292 neurons spike during the first 5 seconds of field application, and 64 % of the
293 neurons fire already within 2 to 3 seconds after the field is turned on (Figure 3E). A
294 histogram of the latencies of all cells exposed to 5 s field stimulation was fitted with a
295 Poisson distribution giving an expectation value of 2.18 ± 0.17 s (Figure 3F). This data
296 shows the fastest magneto-thermal stimulation to date (Chen et al., 2015; Huang et al.,
297 2010). Next, we determined whether magneto-thermal stimulation is also capable of
298 activating quiescent neurons, which were not already near the depolarization threshold.
299 We defined neurons with at least one calcium transient during any five-second period as
300 active. At basal conditions, 53.7 ± 1.6 % of the neurons were active in cultures. Five-
301 second AMF application increase the active population to 80.5 ± 5.1 % of neurons
302 (Figure 3G). We showed that five seconds of magneto-thermal stimulation not only
303 increases the firing rates of already active neurons (Figure 3D), but also increases the
304 percentage of active cells in a population (Figure 3G).

305 **Magnetothermal genetic stimulation of the motor cortex evoked mice to run along** 306 **the periphery of the arena**

307 Next, we verified that that thermal magnetothermal genetic stimulation in the brain
308 could be specific and sufficient to evoke precise behavior in an awake, moving animal.
309 We aimed to evoke a response in freely moving, awake mice, that could be easily and
310 rapidly detected. Repeatable on and off switching with reasonable latencies would
311 demonstrate causality. Specifically, we chose several motor responses which have
312 been previously evoke with chemogenetic or optogenetic activation.

313 Successful secondary motor cortex activation evoking running has been reported
314 using optogenetics (Gradinaru et al., 2007). We aimed to reproduce these responses,
315 using magnetothermal stimulation of motor cortex neurons (Figure 4 - figure supplement
316 2). While some expression of TRPV1 in the rodent brain has been reported (Basbaum
317 et al., 2009), robust magnetothermal genetic stimulation requires uniform, sustained
318 over-expression of TRPV1 in the targeted neurons. We achieved TRPV1
319 overexpression in the mouse motor cortex by delivering adeno-associated virus
320 serotype 5 (AAV5) as a vehicle for the TRPV1 transgene under the neuron specific
321 synapsin-1 promoter hSyn (AAV5-hSyn-TRPV1) by stereotactic injection (Kügler et al.,
322 2003). However, AAV is too small to package a vector encoding TRPV1 and a

323 fluorescent protein marker. Hence, for some experiments, we also created a lentivirus
324 carrying the genes for TRPV1 and a red fluorescent protein with nuclear targeting
325 sequence behind an internal ribosome entry site (EF1a-TRPV1-IRES-DSRed). Both,
326 AAV5 and lentivirus, led to robust expression in-vivo, permitting stimulation of specific
327 behavior.

328 Motor cortex neurons were heat sensitized, by unilaterally injecting AAV5-hSyn-
329 TRPV1 (Carvalho-de-Souza et al., 2015; Lein et al., 2007). Two to four weeks later, 500
330 - 600 ng of antibody conjugated MNPs were injected in the same location. (AP = 1, ML
331 = 0.5, DV = 0.5 (all in mm)). Using immuno-histology, we confirmed virus induced
332 TRPV1 expression and binding of MNPs to neurons in the targeted motor cortex area
333 (Figure 4 - figure supplement 1).

334 All 6 mice in a total of 14 trials began running along the periphery of the
335 observation arena (AMF was 7.5 kA/m and 570 kHz; Figure 4A, B, Figure 4 - figure
336 supplement 4). To illustrate the contrast between the induced and the resting behaviors,
337 the track of the head (color marked for automated object recognition) of a representative
338 mouse is shown in Figure 4C. The running along the periphery of the circular arena,
339 recorded during field application (shown in red) (Video 1) is in sharp contrast to the
340 exploratory/resting tracks, observed in the absence of AMF. Control data acquired from
341 the same mouse before MNP injection, and again between each trial showed randomly
342 oriented slower locomotion, not confined to the periphery (Video 2). Shortly after the
343 AMF application began, the mouse initiated running, which slowed down quickly after
344 the AMF was removed (Figure 4D). The linear running speed of the mouse increased
345 from 5.3 ± 2.75 mm/s to 83.8 ± 3.75 mm/s (Figure 4E; one mouse, four trials, $p = 5.9 \cdot 10^{-6}$,
346 95% C.I. [0.9, 9.7] and [77.8, 89.8] mm/s). The angular speed increased from $0.21 \pm$
347 0.19 revolution per minute to 3.27 ± 0.30 rev/min (Figure 4F; $p = 0.0003$). Over all 14
348 trials in 6 mice, the angular speed was significantly faster during AMF applications, 2.81
349 ± 0.20 rev/min, as compared to 0.34 ± 0.08 rev/min during the rest periods between the
350 fields (Figure 4G; $p = 5.2 \cdot 10^{-9}$; 95% C.I. [0.29, 0.39] and [2.69, 2.93] rev/min). Figure 4
351 supplement 2 shows 7 individual responses to the simulation (4 mice). In all trials, we
352 observed a strong running response, but some mice changed directions occasionally.
353 Hence, we plot the angular distance travelled, in addition to the angular displacement.

354 Repeat stimulation of the same animal evoked increased locomotion reliably in
355 each trial. Figure 4D shows four one-minute field applications within a 15-minute trial.
356 Repeated sessions on the same mice demonstrate that the sensitization persists over
357 several days (Figure 4 - supplement 3). There is a tight temporal correlation between
358 AMF heating and the observed behavior: Each time, shortly after the AMF is applied,
359 the mouse begins to run. The stimulated ambulation persists throughout the duration of
360 the field application and ends shortly after the AMF is removed. For an AMF strength of
361 7.5 kA/m rms at 570 kHz, the behavioral response began on average 22.8 ± 2.6 s ($n =$
362 14, 6 mice, Figure 4H) after the beginning of the AMF. This latency of behavior onset is
363 consistent with the fast in-vitro response, because heating depends on the square of the
364 AMF strength, which for the in-vivo case was about one third of that in in-vitro
365 experiments. Performing AMF heating on MNP decorated HEK cells showed that lower
366 the field strength by a third increased the required time to reach a two-degree increase
367 to 20s (Figure 2 - supplement 1). The delay is comparable to optogenetic stimulations in
368 the motor cortex, also using virus delivered activator genes (Wang et al., 2012). After
369 the AMF is terminated the ambulation behavior continued for 14.7 ± 2.5 s, likely the time
370 required to cool the membrane bound MNPs (Figure 4H). Using membrane bound
371 nanoparticles for magnetothermal neuro-stimulation ensures fast on and off kinetics
372 because only a miniscule volume of space is heater and cooled.

373 Mice injected with only AAV5-hSyn-TRPV1 virus or only MNPs showed no
374 response to AMF application (Video 6 and 7 respectively) demonstrating that neither
375 MNP injection nor TRPV1 expression alone is sufficient to evoke the response.
376 Observable stimulation occurred only when AMF was applied in the presence of the
377 temperature gated ion channel, TRPV1, and the energy transducing MNPs in the same
378 brain locations. For animals lacking either TRPV1 overexpression or MNP, AMF
379 application caused no significant deviation from baseline rotation speed (4 individual
380 mice for each, Figure 4I). On the other hand, in all mice injected with both MNP and
381 TRPV1 at the same brain location, angular speed increased significantly with AMF, 3.17
382 ± 0.17 rev/min compared to the baseline speed of 0.42 ± 0.07 rev/min ($n = 10$, $p =$
383 $1.1 \cdot 10^{-5}$; unpaired T-test; 95% C.I. [0.32, 0.52] and [2.94, 3.40] rev/min) (Figure 4I).
384 Membrane targeting the MNPs is essential as animals injected with virus and MNPs

385 without the anti-A2B5 antibody were not insensitive to the AMF application (Figure 4I,
386 Figure 4 - figure supplement 4).

387

388 **Deep brain magnetothermal genetic stimulations in striatum causes rotation** 389 **around body axis**

390 Next, we investigated the effectiveness of magnetothermal genetic stimulation in
391 the striatum, a deep brain region. Chemogenetic activation of the caudate putamen
392 nuclei in the striatum has previously been shown to evoke increased locomotion in the
393 form of rotation around the body axis (Arenkiel et al., 2008; Kreitzer and Malenka,
394 2008). To replicate these results with magnetothermal stimulation, we injected AAV5-
395 hSyn-TRPV1 virus and MNPs into the caudate putamen nuclei in the dorsal striatum, 3
396 mm deep (AP = 0, ML = 2.3 from bregma) (Li et al., 2015; Oh et al., 2014). Immuno-
397 histology confirmed successful TRPV1 over-expression, MNP injection to the target
398 (Figure 5 - figure supplement 2 and 3), and good overlap of both (Figure 5 - figure
399 supplement 4). During AMF application, the mouse turns around its body axis, so that its
400 head tracks circles of 22 ± 5 mm radius (Figure 5A - C, Video 3). These turns were very
401 regular and quick (19.3 ± 2.2 mm/s; Figure 5D), resulting in 4.7 ± 0.8 revolutions per
402 minute (Figure 5E). This behavior was very different from the running motion observed
403 during motor cortex activation, where the mice ran at speeds of 83.8 ± 3.75 mm/s, close
404 to the edge of the arena, which has a radius of 50 mm. In this case, the turn radii of the
405 circles made by the mice were considerably smaller, and the linear speed lower. The
406 turning motion evoked by stimulating in the striatum was very reproducible from trial to
407 trial and across animals (Figure 5F, 12 trials, 4 animals). The mice turned contralateral
408 to the injection in 11 out of 12 trials and did never reverse the direction of turning after
409 initiating the motion.

410 The average response of 4 striatum targeted mice in 12 trials was a 6-fold increase
411 in angular speed during AMF activation, 2.86 ± 0.19 rev/min compared to a baseline
412 rate of 0.47 ± 0.09 rev/min (Figure 5G; $p = 3.4 \cdot 10^{-7}$; unpaired T-test; 95% C.I. [0.42,
413 0.56] and [2.71, 3.01] rev/min). The observed response is consistent with a prior report
414 of dorsal striatum stimulation by capsaicin activation of TRPV1 channels at the same
415 brain coordinates (Arenkiel et al., 2008).

416 In addition to multiple stimulation trial during one session, we performed several
417 sessions successfully over 54 hours (Figure 5 - figure supplement 1).

418

419 **Magnetothermal genetic deep brain stimulation at the ridge between dorsal and** 420 **ventral striatum causes freezing of gait**

421 To evoke magnetothermally a response that does not involve increased locomotion,
422 we aimed to demonstrate stimulation freezing of gait. The Deisseroth team showed that
423 optogenetic stimulation near the ridge between dorsal and ventral striatum inhibits
424 voluntary locomotion (Gradinaru et al., 2009; Kravitz et al., 2010). Therefore, we took
425 advantage of the fact that the stimulation depth is only limited by brain region
426 accessibility in terms of virus and MNP delivery, and injected AAV5-hSyn-TRPV1 virus
427 and MNPs at the ridge between dorsal and ventral striatum (AP = 0.01, ML = 2.3)
428 (Figure 6 - figure supplement 1). Application of AMF caused freezing of gait (FOG),
429 characterized by the inhibition of locomotion, with all four paws locked in place while the
430 mouse was still able to move its head in all directions, neck onward. FOG is common in
431 patients with advanced Parkinson disease (Moore et al., 2008). Figure 6A-C shows
432 tracks of the mouse neck. Ambulatory activities diminished markedly during stimulation,
433 which can also be seen from the paw tracks (Figure 6 - figure supplement 2). Apart from
434 FOG, there was an excessive outward stretching of the limbs along with the inability of
435 the front extremities to follow the head motion (Figure 6D). During AMF application, the
436 average linear speed decreased significantly, from 17.7 ± 2.2 mm/s before stimulation
437 to essentially rest, 1.04 ± 0.13 mm/s (Figure 6C; 2 mice, 6 trials; $p = 0.0006$; unpaired T-
438 test; 95% C.I. [15.4, 20.1] and [0.90, 1.18] mm/s). The tracked speed during the AMF
439 was indistinguishable from that of a fixed marker on the arena floor (0.52 ± 0.11 mm/s).

440

441 **Discussion**

442 Our work demonstrates that magnetothermal genetic stimulation can effectively
443 activate specific neuronal circuits in awake, freely moving mice to evoke defined
444 behaviors quickly, robustly and repeatedly. Three different circuits and behaviors have

445 been stimulated magnetothermally and compared to prior opto- or chemogenetic
446 stimulation of the same circuits: running, in response to motor cortex stimulation (prior
447 optogenetic work: (Gradinaru et al., 2009)); rotation around the body axis, after
448 stimulation deep in the striatum (prior chemogenetic work: (Arenkiel et al., 2008); and
449 freezing of gait, in response to stimulation on ridge between dorsal and ventral striatum
450 (prior optogenetic work: (Kravitz et al., 2010)). We successfully evoked opposing
451 behaviors, running or freezing of gait by targeting the dorsal striatum or the ridge
452 between the dorsal and ventral striatum, respectively, locations in the brain only 1 mm
453 apart. This clearly demonstrates that the evoked behavior is the result of stimulating a
454 specific neuronal circuit, and that the heat generated by the MNPs in response to the
455 AMF is sufficiently localized to the neurons targeted.

456 Magnetothermal genetic stimulation leads rapidly to the targeted motor behavior,
457 observable within 15-20 seconds of AMF activation. This brief delay is not an intrinsic
458 limit of the technique, but rather the result of a weak average field at the site of the
459 mouse head (Figure 4 - figure supplement 5). As the heating rate is proportional to the
460 square of magnetic field strength, the 3-fold weaker field caused approximately 9 times
461 longer latency in the mouse than observed in the in-vitro studies. It is technically
462 feasible to generate AMFs large enough to reduce the latency for magnetothermal
463 stimulation of behavior in mice to times only marginally slower than electrophysiological
464 or optogenetic stimulation, and significantly faster than chemical stimulation using
465 DREADDs (Armbruster et al., 2007). Likewise, our results show that the evoked
466 locomotor behavior diminished quickly within 15 s after removal of the field. Tight
467 temporal on- and off-control is vital for precise correlation of circuit stimulation with
468 behavioral observation, and thus far had only been achieved using optogenetics, but not
469 magneto- or chemogenetics.

470 The short on- and off-time delays of magnetothermal genetic stimulation permit
471 multiple simulations in short observation times. In our experiments, three to four one-
472 minute stimulations were possible within a 10-15 min experiment. Such repeatability is
473 crucial for obtaining statistically significant behavioral data. Other temporal profiles of
474 stimulation are easily achieved, permitting studies of memory formation, or with

475 variations in the assay. Most importantly, stimulation from several seconds to many
476 minutes are easily achievable, filling an important gap between faster optogenetics and
477 slower chemogenetics.

478 In this study, MNPs were bound via the A2B5 antibody, which indiscriminately
479 recognizes all glycosylated membrane proteins. It yielded the highest nanoparticle
480 density on the cell surface and accordingly, achieved the most rapid heating. However,
481 we also successfully used anti-CD56 (Thy-1), anti-CD90 (NCAM) for endogenous
482 membrane proteins, as well as anti-GFP to target overexpressing GFP-labeled
483 membrane proteins. Magnetothermal genetics in tandem with membrane bound
484 nanoparticles provides three major benefits: First, it provides improved localization and
485 neuron specific targeting. The stimulation region is spatially better confined as the
486 antibody binding limits the distance that the MNP diffuse into the brain (Figure 5 - figure
487 supplement 5). Also, only cell types with the specific membrane receptor targeted by the
488 antibody bind the nanoparticles (Figure 5 - figure supplement 6). Second, the heating is
489 restricted to the vicinity of the membrane. This enables orthogonal targeting in which the
490 TRPV1 channel is expressed in one specific cell type and the MNPs are targeted to a
491 second cell type, and magnetothermal stimulation would only occur at their synapse.
492 Third, membrane targeting provides improved temporal resolution because only a
493 minuscule volume near the membrane is heated which cools off immediately after the
494 AMF is removed. This also delivers less overall heat to the brain. Lastly, we obtained
495 robust activation with as little as 500 ng of nanoparticles, which is 200-fold lower than
496 the volume of nanoparticle suspension for of brain neuron stimulation in anesthetized
497 mice (Chen et al., 2015).

498 One concern for magnetothermal stimulation may be that the MNPs either directly or
499 via the membrane heating induce cell death. We successfully repeated stimulation of
500 the same animals for 7 to 8 trials over a few days without observing any change in
501 normal or evoked behavior. Also, histology of brains after 20 one-minute AMF
502 applications, spread over 3 sessions during a 24-hour period, showed intact MNP
503 decorated neurons (Figure 5 - figure supplement 7). Hence, if there is any damage, it is
504 undetectable in histology and behavior. Thermal damage can be avoided by choosing

505 the field strength sufficiently small so that the cooling to the environment limits the
506 possible temperature rise to a few degrees.

507 As magnetothermal genetic stimulation does not require a physical connection to the
508 animal, it offers unprecedented freedom in designing novel behavioral assays. For
509 instance, several animals could share the stimulation arena simultaneously, and only
510 animals injected with MNPs would be affected by the AMF. This provides the ability to
511 study stimulated and unaffected animals simultaneously, either as controls or to study
512 their interaction. Absence of a tether or implant also has the advantage that animals do
513 not carry any external marker, which may interfere with normal social group behavior.
514 Additionally, exclusive to magnetothermal genetic stimulation, stimulation only occurs
515 when the animal is within the magnetic field. Hence, adapting the field geometry allows
516 controlling the stimulation timing and condition. This is ideal for space or location
517 dependent assays such as multi chamber place preference assays when the animals
518 are to be stimulated only when in one chamber.

519 One limitation of the current implementation of magnetothermal genetic stimulation
520 is the power required to generate high AMFs over a large volume. In this study, a 7.5
521 kW power source produced the AMF over a volume of 300 cm³. However, stronger
522 power sources are available to produce AMF in larger volumes, sufficient to cover the
523 entire brain of non-human primates as well as humans. Magnetothermal stimulation
524 may provide an alternative to optogenetics for deep brain stimulation in non-human
525 primates. First, large brains move significantly relative to the skull, potentially displacing
526 electrodes and glass fibers from their original target. As the transducer for
527 magnetothermal stimulation is attached to the cells and not the skull, the stimulation
528 location remains with the originally targeted cells. Second, activation of behavior in non-
529 human primates may require coordinated activation of several distinct brain regions and
530 each region may be larger than the volume covered by an optical fiber (Han, 2012;
531 Inoue et al., 2015). Magnetothermal genetic stimulation can stimulate multiple distinct
532 brain locations easily, as the delivery of the MNP is minimally invasive and the magnetic
533 field covers the entire volume. The actual stimulated volume can be controlled by the
534 MNP amount and rate of injection. Therefore, magnetothermal genetic stimulation is

535 well suited for deep brain stimulation in non-human primates.

536 Just as for other genetic techniques, one hurdle to application in humans will be
537 safety concerns around injecting virus and nanoparticles into the brain. However, the
538 body's reaction to nanoparticle injections has been extensively studied and can be
539 minimized by using a biologically compatible nanoparticle surface coating. The invasive
540 brain surgery currently used to inject the MNP may soon be replaced by MNP delivery
541 via the bloodstream as recent research has shown, that focused ultrasound can
542 transiently make the blood-brain barrier permeable to virus particles (Price, 2015).
543 Overall, magnetothermal neurostimulation offers a series of advantages for deep brain
544 stimulation or silencing in non-human primates and primates.

545 **Materials and methods**

546 **Magnetic Field Generation**

547 Alternating magnetic fields were generated by water-cooled coils, driven by a 7.5 kW
548 power generator from MSI Automation. The instrument is separated into two units
549 (Figure 1C, figure supplement 1). The power source (also the control unit) was some
550 distance away from the microscope while the head stage, on which the hyperthermia
551 coil was mounted, was placed over the microscope stage through an opening in the
552 incubator. The coil was placed directly over the sample chamber. Circulating water
553 cooled any resistive element in the systems. Magnetic field for all in-vitro experiments
554 were generated using a 5 mm Φ , 5 turn copper coil. Field measurements at the
555 samples' site were done separately using a Fluxtrol Magnetic Probe. For in vivo studies,
556 the same instrument was used to power a 10 mm Φ , 2-turn water cooled copper coil
557 (Figure 4A, figure supplement 5).

558 **Magnetic Nanoparticle Preparation**

559 Superparamagnetic core-shell Co-Mn-Ferrite nanoparticles (MNP) with a diameter of
560 12.5 ± 1.0 nm (Figure 1D) were synthesized and characterized according to published
561 methods(Zhang et al., 2015a). The MNP were transferred to water by coating with PMA
562 (poly-isobutylene-maleic anhydride) following published protocols(Lin et al., 2008). The
563 PMA coated MNP were functionalized by covalently attaching fluorescently labeled

564 Neutravidin, which could then bind to a biotinylated antibody.

565 **Experimental and Theoretical Magnetic Nanoparticle Characterization**

566 Magnetization data for Horse spleen ferritin was generously shared with us by Dr. I.
567 Orue (SGIker, Universidad del País Vasco UPV/EHU, 48940 Leioa, Spain).
568 Magnetization data for the synthesized core-shell MNP, Co-Mn-Ferrite nanoparticles
569 (MNP) was also measured by Dr. I. Orue (Figure S1E). For calculation of magnetic
570 dipole interaction energy (Figure 1 - figure supplement 4), spherical MNPs were
571 assumed to be point dipoles, with moments aligned perpendicular to the dipole axis.
572 The interaction energy, then is given by

$$573 \quad U(r) = \frac{\mu_0}{4\pi r^3} \cdot (2\mu^2),$$

574 where μ is the magnetic moment of individual nanoparticles separated by a distance r .

575 For calculation of SLP values (Figure 1 - figure supplement 4), a saturation
576 magnetization value of 340 μB was used for horse spleen ferritin. Anisotropy constant
577 was obtained from reported values (García-Prieto et al., 2016). Saturation
578 magnetization and anisotropy constant for core-shell MNPs were obtained from
579 previous measurements (Zhang et al., 2015b). The permissible magnetic field strength
580 for each frequency points were calculated using the accepted limit of field attenuation
581 (and ensuing eddy current heating in tissues) (Atkinson et al., 1984; Chen et al., 2015).
582 Power delivered in W/g of particles is then given by:

$$583 \quad P_{particle} = \pi\mu_0\chi_0 H_0^2 f \frac{2\pi f\tau}{1 + (2\pi f\tau)^2}$$

584 Here, the magnetic susceptibility χ_0 follows Langevin's equation and is a function of both
585 the magnetic field amplitude H and T (Rosensweig, 2002).

586 **Molecular Thermometry**

587 To measure the local heating near the nanoparticle decorated cell surface, we used
588 the fact that the fluorescence lifetime as well as intensity of molecular fluorophores and
589 fluorescent proteins decrease with increasing temperature (Figure 1 - figure supplement
590 3).

591 *Fluorescent labeling of Neutravidin and binding to MNPs*

592 Neutravidin (31000, Thermo Scientific), dissolved in Phosphate-buffered saline
593 (PBS) at 2 mg/ml (pH 7.34), was labeled with DyLight™ 550 NHS ester dye (62262,
594 Life Technologies), or Alexa 647 dye (A37573, Life technologies) by mixing Neutravidin
595 stock solution with 5 times molar excess of the fluorophore, and incubated in dark for 2
596 hours. Excess dye (molecular weight, under 3kDa) was removed using a Microcon 10
597 kDa centrifugal filter (EMD Millipore), 8000 r.c.f. Carboxylic groups on surface of the
598 PMA-MNP (1mg/ml) were activated with 0.5 mg/ml of EDC [1-ethyl-3-(3-
599 dimethylaminopropyl) carbodiimide hydrochloride] (22980, Life technologies) and 1.4
600 mg/ml of Sulfo-NHS (N-hydroxysulfosuccinimide) (24510, Life technologies). Activated
601 MNPs were re-suspended in PBS, and added dropwise to Neutravidin -Dylight 550 or -
602 Alexa 647, in 10 times molar excess. After reacting for two hours in the dark, the
603 reaction was quenched with 10 mM Hydroxylamine buffer. Unbound Neutravidin was
604 removed by washing MNP in 300 kDa cut-off centrifuge filters (8000 r.c.f).

605 **Fluorescence Microscopy**

606 *Image Acquisition and Imaging Conditions*

607 Fluorescence intensities of GCaMP6f as a measure for Ca²⁺ levels, and DyLight
608 550 dye (Life Technologies) as molecular thermometer, were recorded using an
609 inverted epifluorescence microscope (ZEISS AXIO OBSERVER A1.0m). Cells grown on
610 12 mm glass coverslip were secured in a non-conducting chamber (ALA MS-
611 512DWPW) and placed on the XY stage of the microscope. A custom-built
612 environmental incubation chamber enclosed the microscope. Temperature inside the
613 chamber was set before the start of the experiment and kept stable at 33.0 ± 1.0 oC.
614 The fluorophores were excited using a HBO 200 mercury short arc lamp with
615 appropriate filters. The emission was collected with a 40x NA 0.75 Zeiss objective lens
616 and recorded with an Andor NEO sCMOS camera controlled by micromanager
617 software(Edelstein et al., 2014). Continuous videos were acquired with an exposure
618 time of 100 ms at 2 × 2 binning, and saved as stack of uncompressed .TIFF files.
619 Uniblitz electronics VS14S2T0 shutter, driven by Uniblitz VCM-D1 driver was used to
620 synchronize excitation light illumination with camera acquisition times via micromanager
621 software.

622 *Microscopy in alternating magnetic field*

623 The alternating magnetic fields induce eddy currents in the metallic microscope
624 objective, heating it up. The thermal expansion of the objective lens may cause optical
625 distortions and focus changes. To correct these in real time, we used a fast, customized
626 piezoelectric autofocus system (Motion X Corporation, 780 nm laser interferometer
627 based). The autofocus laser beam was coupled in the optical path of the microscope by
628 a dichroic mirror, focused through the objective lens onto the coverslip bottom and
629 reflected back into the interferometer (Figure 1 - figure supplement 1). Therefore, it not
630 only detects and corrects changes in separation between coverslip and objective lens
631 but also internal optical changes.

632 **Labeling Cells with MNP**

633 *HEK 293T cells*

634 HEK cells growing on 12 mm glass coverslip, 50 % confluent were co-transfected
635 with plasmid expressing Biotin acceptor arm AP-CFP-TM and plasmids BirA enzyme (p-
636 DISPLAY)(Chen et al., 2005) (0.4µg each). Following transfection, 5uM of Biotin was
637 fed to growing cells. 24 hours later the coverslips were transferred to the imaging
638 chamber (ALA MS-512DWPW) in 200 µl physiological salt solution (PSS, ingredients in
639 mM: CaCl₂ 2, NaCl 151, MgCl₂ 1, KCl 5, HEPES 10, and Glucose 10, pH 7.3). MNP
640 conjugated with neutravidin-DL550 (0.5 mg/ml) were added (2 µl). After 5 minutes, the
641 dish was perfused with PSS buffer to remove unbound particles.

642 *Neuronal culture*

643 Nanoparticles were targeted to the neuronal cell membrane via biotinylated IgM
644 antibody (433110, Invitrogen). Neuronal cultures grown on 12 mm coverslip were
645 loaded in imaging chamber (ALA scientific) holding 200 µl of imaging buffer pH.7.34.
646 Biotinylated antibody (2 µg/ml) was added, incubated for 10 minutes, before being
647 washed off by perfusing with HEPES buffer pH 7.3. Neutravidin conjugated
648 nanoparticles were then added at 10 µg/ml, and after 5 minutes the unbound
649 nanoparticles were washed off.

650 **Molecular Cloning and Virus Packing**

651 Rat TRPV1(VR1) in pcDNA3 was a gift from Dr. Julius (UCSF). The lentivirus vector
652 pLKO.1-EF1a-TRPV1-IRES-DSRed was constructed as follows. A TRPV1 pcr fragment
653 (5' Sal I and 3' Hpa I) was subcloned into pLKO.1-EF1a-IRES-DSRed with a 5' primer
654 (5'-GCG TCG TCG GTC GAC GCC ACC ATG GAA CAA CGG GCT AGC TTA GAC
655 TC-3') and a 3' primer (5'-GCG TCG TCA AGC TTT TAT TTC TCC CCT GGG ACC
656 ATG GAA TC-3'). AAV5-hSyn-TRPV1 was constructed by generating a TRPV1 pcr
657 fragment (5' Sal I and 3' EcoR I) with 5' primer (5'GCG TCG TCG GTC GAC GCC ACC
658 ATG GAA CAA CGG GCT AGC TTA GAC TC-3') and 3' primer (5'-GCG TCG TCG AAT
659 TCT TAT TTC TCC CCT GGG ACC ATG GAA TC-3'). The TRPV1 pcr product was
660 cloned into Sal I and EcoR I of pAAV-hSyn-HA-hM4D(Gi)-mCherry a gift from Bryan
661 Roth (Addgene plasmid #50475). All constructs were sequence verified. The adeno-
662 associated virus, AAV5-hSyn-TRPV1, was generated at the Virus Vector Core at the
663 University of North Carolina at Chapel Hill. The qPCR titer was 1.5×10^{12} . Packing of
664 the pLKO.1-EF1a-TRPV1-IRES-DSRed plasmid into lentivirus followed established
665 Protocols(Boyden Et Al., 2005).

666 **In-Vitro Experiments on Neurons**

667 *Preparation of neurons*

668 After transfection or nucleofection, the neuronal Cultures were placed in incubator
669 for next 24 - 48 hours to express the proteins. During this time, 1 μ M TTX (Tetrodotoxin)
670 was added to Neuronal culture to minimize endogenous activity. For imaging, the TTX
671 was washed out, and the neurons were placed in Tyrode solution (NaCl 145, CaCl₂ 2,
672 MgCl₂ 1, KCl 2.5, HEPES 10, Glucose 20; all in mM). The imaging buffer also
673 contained synaptic blockers DLAP-5 25 μ M, NBQX 10 μ M, and Gabazine 20 μ M, and
674 the osmolality was adjusted to 310-315 mOsmole/L.

675 *TRPV1 Activation by Heated Buffer*

676 Hippocampal Neuronal cells transiently expressing GCaMP6f and rat TRPV1 were
677 investigated for TRPV1 activation by heat. GCaMP6f acted as marker for nucleofected
678 neurons and as genetically encoded calcium indicator. TRPV1 activation by heat was

679 achieved by perfusion of preheated imaging buffer (HEPES 10 mM, NaCl 140 mM,
680 CaCl₂ 2 mM, MgCl₂ 1mM, KCl 4 mM, Glucose 10mM). Perfusion buffers were heated
681 using an inline heater (SH-27B, Warner Instruments) with an integrated temperature
682 feedback (TC-324C). Bath temperature was monitored using Neoptix ReFlex optical
683 thermal probe. A custom built microscope enclosure chamber maintained the ambient
684 temperature 33 ± 1.0 °C. As a measure of temperature driven TRPV1 activation,
685 transient rise in intracellular Ca²⁺ level was recorded from GCaMP6f fluorescence
686 intensity changes (Figure 1F; Figure 1 - figure supplement 2B; Figure 3B).

687 **Evoking and Observing Animal Behavior**

688 *Animal Surgeries for Stereotaxic Injection of Virus or Nanoparticles*

689 Male BALB/c mice (3 - 4 week old, weighing 15 - 20 g) were obtained from Harlan
690 Laboratories, and housed in the live animal facility (LAF) under 12 h light - dark cycle in
691 accordance with approved animal protocols from the University at Buffalo SUNY
692 Institutional Animal Care.

693 Mice were anesthetized by mixture of Ketamine and Xylazine (100 mg of Ketamine
694 and 10 mg of Xylazine per kilo gram of body weight i.p.). Burpenorphine (0.1 mg per kg
695 body weight, s.c.) was administered as pre-operative pain medicine. Anesthetized
696 mouse was mounted on Stereotaxic frame (Stoelting) with help of ear bars and tooth
697 bar. The head was shaved and rubbed with betadine and then ethanol. The Skin was
698 retracted and the periosteum was removed at the site. The scalp was opened and hole
699 was drilled in the skull, through which a 33-gauge needle fitted in 5 µl syringe was
700 inserted into the motor cortex (MC) or striatum1 (St1), or St2, left or right (See
701 supplementary Table 1 for injection coordinates). Using that syringe and an automated
702 syringe pump (World Precession Instruments) 600 nl virus were infused at a rate of 2
703 nl/s. The injection needle was raised 0.01 mm and kept in place for 5-10 minutes and
704 slowly removed. The mouse scalp was sutured and anti-inflammatory Caprofen (5
705 mg/ml) was given for two days' post-surgery. All surgical procedures were done under
706 aseptic conditions. Animals were housed for two weeks to allow for viral expression
707 before any behavioral experiments were initiated.

708 *Nanoparticle Delivery at Targeted Site in Brain*

709 Equal moles of MNP conjugated with Neutravidin and biotinylated antibody were
710 mixed at 1 mg/ml. The mice were anesthetized using Xylazine and Ketamine, fixed in a
711 stereotactic frame, the periosteum removed, and the pre-drilled hole from the virus
712 injection 2 to 4 weeks earlier was identified. Then, 600 nl of MNP-antibody was injected
713 at the same site as the virus injection two weeks back, following exactly the same
714 procedure (see above). The procedure was completed within 45 minutes and mice
715 recovered within 1 hour, post anesthesia. Animals were placed in fresh cage and
716 housed for 12 hours before initiating experiment.

717 *Recording Animal Behavior*

718 For each session, the animals were placed in a circular observation area. Sessions
719 were limited to 30 minutes, including 10 minutes habituation, and 15 – 20 minutes
720 experiment, during which 3 or 4 one-minute long AMF applications were given.

721 A consumer camera (Nikon D810) was used to record video (HD720, 60fps) of the
722 mice before, during and after the magnetic field stimulation. For the ‘freezing of gait’
723 response caused by stimulation in the striatum, a different consumer camera (SONY
724 DSC-H50) at 20fps was used. To minimize influence of the light and shadows on the
725 mouse’s behavior, the light levels were kept extremely low (camera sensitivity set at
726 ISO 12,800). The videos (12-18 min in length, 1.2-2.4 Gb, uncompressed) were
727 transferred to an iMac27” computer. Red marks were made on the mice with common
728 non-toxic finger paints (Crayola) to aid motion tracking via computer vision.

729 **Calcium Data Analysis**

730 Fluorescence microscopy movies were recorded (Micromanager) as TIFF stacks
731 and post processing and ROI (region of interest) mean intensity data were extracted
732 using FIJI (Fiji Is Just ImageJ). Relevant ROIs were cropped from the video files and
733 registration (using the Stack Registration plugin) was done to eliminate any x-y shift in
734 the images over the video frames. Afterwards, an intensity based threshold operation
735 was done to convert non-cellular dimmer background pixels to NAN (Figure 3 - figure
736 supplement 1A). A polygonal ROI was then drawn to cover the cell body. The mean
737 intensity data (bit depth) of all the pixels within that ROI was saved with respective
738 frame numbers. The intensity versus time data was then exported to IgorPro, which was

739 used for further analysis.

740 *Intensity normalization*

741 After importing the mean ROI intensity data as a wave in Igor Pro, constant dark
742 noise values were subtracted from all points in the wave. The dark noise is the mean
743 signal recorded by the camera under no illumination conditions. All experiments were
744 done in the same dark room and the dark noise value deviated little from experiment to
745 experiment and is mostly dependent of the camera exposure times. After, the dark
746 noise cancellation, a further baseline subtraction was done for bleach correction, if
747 substantial bleaching based decay in baseline was observed. For this, the baseline was
748 fitted to an exponential function and a modified signal was obtained according to
749 $F(t) = F'(t) + (F'(0) - F'_{fit}(t))$. Here, $F'(t)$ is the signal values obtained after dark

750 noise cancellation and $F'_{fit}(t)$ is the corresponding exponential fit function. The result,
751 hence obtained was normalized and converted to percentage change in fluorescence.
752 The percentage change in fluorescence intensity was given by :

$$\frac{\Delta F(t)}{F_0} = \frac{F(t) - F_0}{F_0} \times 100$$

753 where, F_0 is the bleach corrected baseline ROI intensity and $F(t)$, the intensity at
754 any time t .

755 *Single spike estimation*

756 The intensity change of GCaMP6f makes it sensitive enough for single action
757 potential detection, but its temporal resolution is not high enough to produce temporally
758 isolated spikes corresponding to each firing in an AP train (Chen et al., 2013). To
759 extract action potential events from a GCaMP6f fluorescence signal (Ca²⁺ peaks), we
760 first isolated all peaks from the intensity normalized data corresponding to each neuron
761 with a mean maximum of about 5% (of the baseline). The peaks were then averaged
762 and a mean peak profile was created (Figure 3 - figure supplement 1B, C). The
763 average peak wave was then interpolated linearly to increase the temporal resolution to

764 100 Hz.

765 *AP train reconstruction*

766 A null wave of time length equal to that of the original data, but of 100 Hz frequency
767 (in contrast to 10 Hz, for the original data) was created. The null wave was then
768 converted to a binary wave, with 1s at the location of estimated AP spikes (Figure 3 -
769 figure supplement 1D, E; black bars). The estimated single spike wave was then
770 convolved with the binary wave. An overlay of the normalized data and its
771 corresponding convolution based reconstruction is shown in Figure 3 - figure
772 supplement 1D, E. A histogram of the residue of the original and the reconstructed
773 waves was fitted to a Gaussian function. The locations of the 1s in the binary wave were
774 dynamically adjusted to obtain an overall sigma of less than 2%. The binary wave
775 obtained after optimization gave the temporal function of AP events for each recording.

776 **Behavioral Analysis of Freely Moving Mice**

777 *Motion Tracking*

778 For all motor behavior analysis, the position of the red neck marker was recorded
779 automatically using the free video analysis and modeling tool TRACKER built by
780 Douglas Brown on the Open Source Physics Java framework. For the active motor
781 responses, every 2nd frame was analyzed, resulting in 30 position measurements per
782 second. The coordinates produced by the tracker were transferred to IgorPro
783 (Wavemetrics) for further analysis and graphing. For motion tracking of the 'freezing of
784 gait' response, the position of each paw was tracked every 1.2 seconds and the speed
785 of the mouse was calculated as the absolute value of the linear speed averaged over 3
786 seconds. For other recordings involving rapid mouse movements, linear speed and an
787 angular speed are reported as an average over 500 ms. To visualize the spatial motion
788 XY-plots of the motion in selected time windows were generated directly from the raw
789 XY coordinates. To visualize the temporal flow, we also plot the XY-coordinates as
790 function of time.

791 *Video Editing for Presentation*

792 Videos chosen for publication were edited using VSDC video editor software (Flash-

793 Integro) and Lightworks. Raw videos were compressed using H.264 encoder and
794 downsampled to 15 fps and sped up 3X for fast download and observation. The red
795 marks on the neck were applied to aid motion tracking. Field application periods are
796 indicated on the bottom right, while the MNP injection sites in the brain are indicated on
797 the bottom left.

798

799 **Histology**

800 Frozen coronal Rostral to caudal brain sections were prepared following standard
801 protocols. The 75 μ m thick slices were stained for subsequent laser confocal imaging.

802 Soma and dendrites of neurons were marked using a rabbit anti microtubules-
803 associated- protein (MAP2) antibody (ab32454, Abcam)(24 hours, 1:500), in conjunction
804 with anti-rabbit IgG Alexa 488 (ab150077, Abcam)(1 hour).

805 MNPs coated with PMA were conjugated with Neutravidin, tagged with ATTO 488. To
806 boost the fluorescence signal, some brain slices were incubated with Biotin-PEG,
807 tagged with Alexa 647 dye (24 hours, 1:500).

808 AAV5 or lenti-virus was used for TRPV1 channel delivery to the brain. The lenti-virus
809 delivered also a nuclear marker marker (NLS-mCherry). As the AAV5 did not contain
810 any marker, the AAV slices were incubated with anti-TRPV1 antibody (ab31895,
811 Abcam), which we directly conjugated with Alexa 647.

812 **Author contributions**

813 The project was conceived by AP. AP, SQ, and RM authors contributed to design of the
814 research. RM and SQ performed cell stimulation experiments. SQ and RM developed
815 animal models, injected the mice, and performed behavior stimulation experiments. RM
816 measured SLP, analyzed cell stimulation and the local heating measurements, and
817 imaged brain slices. QZ and PP synthesized the MNPs. ICR optimized the MNP coating
818 and targeting. RM, SQ and AP analyzed the data and wrote the manuscript.

819

820 **Acknowledgement**

821 We thank Wolfgang J. Parak (University at Marburg, Germany) for a gift of MNPs,

822 Mathew Paul (University at Buffalo) for lending us his micro-pump, Jason Myers
823 (University at Buffalo) for molecular cloning and preparation of cultured hippocampal
824 neurons, and Sara Parker (University at Buffalo) for the histology. TRPV1 was a gift
825 from David Julius (UCSF), pGP-CMV-GCaMP6f a gift from Douglas Kim (Addgene
826 plasmid # 40755), and GL-GPI-mCherry from Gerald Baron (US Dept. of Health and
827 Human Services). This work was supported by NIH grants was supported by HSFP
828 project grant RGP0052/2012 and NIH grant R01MH094730.

829

830 **Competing financial interests**

831 The authors declare no competing financial interests.

832 **References**

833 Arenkiel, B.R., Klein, M.E., Davison, I.G., Katz, L.C., Ehlers, M.D., 2008. Genetic control of neuronal
834 activity in mice conditionally expressing TRPV1. *Nat Methods* 5, 299–302.
835 doi:10.1038/nmeth.1190

836 Armbruster, B.N., Li, X., Pausch, M.H., Herlitze, S., Roth, B.L., 2007. Evolving the lock to fit the key to
837 create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc. Natl.*
838 *Acad. Sci. U. S. A.* 104, 5163–8. doi:10.1073/pnas.0700293104

839 Atkinson, W.J., Brezovich, I.A., Chakraborty, D.P., 1984. Usable Frequencies in Hyperthermia with
840 Thermal Seeds. *IEEE Trans. Biomed. Eng. BME-31*, 70–75. doi:10.1109/TBME.1984.325372

841 Baffou, G., Berto, P., Bermúdez Ureña, E., Quidant, R., Monneret, S., Polleux, J., Rigneault, H., 2013.
842 Photoinduced heating of nanoparticle arrays. *ACS Nano* 7, 6478–6488.
843 doi:10.1021/nn401924n

844 Banghart, M., Borges, K., Isacoff, E., Trauner, D., Kramer, R.H., 2004. Light-activated ion channels for
845 remote control of neuronal firing. *Nat. Neurosci.* 7, 1381–6. doi:10.1038/nn1356

846 Basbaum, A.I., Bautista, D.M., Scherrer, G., Julius, D., 2009. Cellular and Molecular Mechanisms of
847 Pain. *Cell* 139, 267–284. doi:10.1016/j.cell.2009.09.028

848 Bean, C.P., Livingston, J.D., 1959. Superparamagnetism. *J. Appl. Phys.* 30, S120.
849 doi:10.1063/1.2185850

850 Boyden, E.S., Zhang, F., Bamberg, E., Nagel, G., Deisseroth, K., 2005. Millisecond-timescale,
851 genetically targeted optical control of neural activity. *Nat. Neurosci.* 8, 1263–8.
852 doi:10.1038/nn1525

853 Brown, Jr, W.F., 1963. Thermal fluctuations of a single-domain particle. *Phys. Rev.* 130, 1677–1686.

854 Carvalho-de-Souza, J.L., Treger, J.S., Dang, B., Kent, S.B.H., Pepperberg, D.R., Bezanilla, F., 2015.
855 Photosensitivity of Neurons Enabled by Cell-Targeted Gold Nanoparticles. *Neuron* 86, 207–
856 217. doi:http://dx.doi.org/10.1016/j.neuron.2015.02.033

- 857 Chen, B.T., Yau, H.J., Hatch, C., Kusumoto-Yoshida, I., Cho, S.L., Hopf, F.W., Bonci, A., 2013. Rescuing
858 cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking. *Nature*
859 496, 359–362. doi:10.1038/nature12024
- 860 Chen, R., Romero, G., Christiansen, M.G., Mohr, A., Anikeeva, P., 2015. Wireless magnetothermal deep
861 brain stimulation. *Science* 347, 1477–80. doi:10.1126/science.1261821
- 862 García-Prieto, A., Alonso, J., Muñoz, D., Marcano, L., Abad Díaz de Cerio, A., Fernández de Luis, R.,
863 Orue, I., Mathon, O., Muela, A., Fdez-Gubieda, M.L., 2016. On the mineral core of ferritin-like
864 proteins: structural and magnetic characterization. *Nanoscale* 8, 1088–99.
865 doi:10.1039/c5nr04446d
- 866 Gradinaru, V., Mogri, M., Thompson, K.R., Henderson, J.M., Deisseroth, K., 2009. Optical
867 deconstruction of parkinsonian neural circuitry. *Science* 324, 354–9.
868 doi:10.1126/science.1167093
- 869 Gradinaru, V., Thompson, K.R., Zhang, F., Mogri, M., Kay, K., Schneider, M.B., Deisseroth, K., 2007.
870 Targeting and readout strategies for fast optical neural control in vitro and in vivo. *J. Neurosci.*
871 27, 14231–14238. doi:10.1523/JNEUROSCI.3578-07.2007
- 872 Grandl, J., Kim, S.E., Uzzell, V., Bursulaya, B., Petrus, M., Bandell, M., Patapoutian, A., 2010.
873 Temperature-induced opening of TRPV1 ion channel is stabilized by the pore domain. *Nat*
874 *Neurosci* 13, 708–714.
- 875 Grewe, B.F., Langer, D., Kasper, H., Kampa, B.M., Helmchen, F., 2010. High-speed in vivo calcium
876 imaging reveals neuronal network activity with near-millisecond precision. *Nat. Methods* 7,
877 399–405. doi:10.1038/nmeth.1453
- 878 Han, X., 2012. Optogenetics in the nonhuman primate. *Prog. Brain Res.* 196, 213–233.
- 879 Hofmann-Amttenbrink, M., von Rechenberg, B., Hofmann, H., 2009. Superparamagnetic
880 nanoparticles for biomedical applications, *Advanced drug delivery reviews.*
881 doi:10.1016/j.addr.2012.10.008
- 882 Hooks, B.M., Mao, T., Gutnisky, D.A., Yamawaki, N., Svoboda, K., Shepherd, G.M.G., 2013. Organization
883 of Cortical and Thalamic Input to Pyramidal Neurons in Mouse Motor Cortex. *J. Neurosci.* 33,
884 748–760. doi:10.1523/JNEUROSCI.4338-12.2013
- 885 Huang, H., Delikanli, S., Zeng, H., Ferkey, D.M., Pralle, A., 2010. Remote control of ion channels and
886 neurons through magnetic-field heating of nanoparticles. *Nat. Nanotechnol.* 5, 602–606.
887 doi:10.1038/nnano.2010.125
- 888 Inoue, K.-I., Takada, M., Matsumoto, M., 2015. Neuronal and behavioural modulations by pathway-
889 selective optogenetic stimulation of the primate oculomotor system. *Nat. Commun.* 6, 8378.
- 890 Kravitz, A. V., Freeze, B.S., Parker, P.R.L., Kay, K., Thwin, M.T., Deisseroth, K., Kreitzer, A.C., 2010.
891 Regulation of parkinsonian motor behaviours by opt... [Nature. 2010] - PubMed result. *Nature*
892 466, 622–6. doi:10.1038/nature09159
- 893 Kreitzer, A.C., Malenka, R.C., 2008. Striatal Plasticity and Basal Ganglia Circuit Function. *Neuron* 60,
894 543–554. doi:10.1016/j.neuron.2008.11.005
- 895 Kügler, S., Lingor, P., Schöll, U., Zolotukhin, S., Bähr, M., 2003. Differential transgene expression in

- 896 brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units.
897 *Virology* 311, 89–95. doi:10.1016/S0042-6822(03)00162-4
- 898 Lee, J.-H., Jang, J.-T., Choi, J.-S., Moon, S. H. Noh, S.-H., Kim, J.-W. , Kim, J.-G., Kim, I.-S., Park, K. I.,
899 Cheon, J. 2011. Exchange-coupled magnetic nanoparticles for efficient heat induction. *Nature*
900 *Nanotech.* 6, 418–422. doi:10.1038/nnano.2011.95
- 901 Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F., Boguski, M.S.,
902 Brockway, K.S., Byrnes, E.J., Chen, L., Chen, L., Chen, T.-M., Chin, M.C., Chong, J., Crook, B.E.,
903 Czaplinska, A., Dang, C.N., Datta, S., Dee, N.R., Desaki, A.L., Desta, T., Diep, E., Dolbeare, T. a,
904 Donelan, M.J., Dong, H.-W., Dougherty, J.G., Duncan, B.J., Ebbert, A.J., Eichele, G., Estin, L.K.,
905 Faber, C., Facer, B. a, Fields, R., Fischer, S.R., Fliss, T.P., Frensley, C., Gates, S.N., Glattfelder, K.J.,
906 Halverson, K.R., Hart, M.R., Hohmann, J.G., Howell, M.P., Jeung, D.P., Johnson, R. a, Karr, P.T.,
907 Kawal, R., Kidney, J.M., Knapik, R.H., Kuan, C.L., Lake, J.H., Laramée, A.R., Larsen, K.D., Lau, C.,
908 Lemon, T. a, Liang, A.J., Liu, Y., Luong, L.T., Michaels, J., Morgan, J.J., Morgan, R.J., Mortrud, M.T.,
909 Mosqueda, N.F., Ng, L.L., Ng, R., Orta, G.J., Overly, C.C., Pak, T.H., Parry, S.E., Pathak, S.D.,
910 Pearson, O.C., Puchalski, R.B., Riley, Z.L., Rockett, H.R., Rowland, S. a, Royall, J.J., Ruiz, M.J.,
911 Sarno, N.R., Schaffnit, K., Shapovalova, N. V, Svisay, T., Slaughterbeck, C.R., Smith, S.C., Smith, K.
912 a, Smith, B.I., Sodt, A.J., Stewart, N.N., Stumpf, K.-R., Sunkin, S.M., Sutram, M., Tam, A., Teemer,
913 C.D., Thaller, C., Thompson, C.L., Varnam, L.R., Visel, A., Whitlock, R.M., Wohnoutka, P.E.,
914 Wolkey, C.K., Wong, V.Y., Wood, M., Yaylaoglu, M.B., Young, R.C., Youngstrom, B.L., Yuan, X.F.,
915 Zhang, B., Zwingman, T. a, Jones, A.R., 2007. Genome-wide atlas of gene expression in the adult
916 mouse brain. *Nature* 445, 168–176.
- 917 Li, N., Chen, T.-W., Guo, Z. V., Gerfen, C.R., Svoboda, K., 2015. A motor cortex circuit for motor
918 planning and movement. *Nature* 519, 51–56. doi:10.1038/nature14178
- 919 Lórenz-Fonfría, V.A., Heberle, J., 2014. Channelrhodopsin unchained: Structure and mechanism of a
920 light-gated cation channel. *Biochim. Biophys. Acta - Bioenerg.*
- 921 Mannix, R.J., Kumar, S., Cassiola, F., Montoya-Zavala, M., Feinstein, E., Prentiss, M., Ingber, D.E., 2008.
922 Nanomagnetic actuation of receptor-mediated signal transduction. *Nat. Nanotechnol.* 3, 36–40.
923 doi:10.1038/nnano.2007.418
- 924 Meister, M., 2016. Physical limits to magnetogenetics. *Elife* 5, e17210. doi:10.7554/eLife.17210
- 925 Nieh, E.H., Kim, S.Y., Namburi, P., Tye, K.M., 2013. Optogenetic dissection of neural circuits
926 underlying emotional valence and motivated behaviors. *Brain Res.*
927 doi:10.1016/j.brainres.2012.11.001
- 928 Pankhurst, Q. a, Thanh, N.T.K., Jones, S.K., Dobson, J., 2009. Progress in applications of magnetic
929 nanoparticles in biomedicine. *J. Phys. D. Appl. Phys.* 42, 224001. doi:10.1088/0022-
930 3727/42/22/224001
- 931 Price, R., 2015. Ultrasound-targeted nanoparticle delivery across the blood-brain barrier. *J. Ther.*
932 *Ultrasound* 3, 1–3. doi:10.1186/2050-5736-3-S1-O20
- 933 Stanley, S.A., Gagner, J.E., Damanpour, S., Yoshida, M., Dordick, J.S., Friedman, J.M., 2012. Radio-wave
934 heating of iron oxide nanoparticles can regulate plasma glucose in mice. *Science* 336, 604–8.
935 doi:10.1126/science.1216753
- 936 Stanley, S.A., Sauer, J., Kane, R.S., Dordick, J.S., Friedman, J.M., 2015. Remote regulation of glucose

937 homeostasis in mice using genetically encoded nanoparticles. *Nat. Med.* 21, 92–98.
938 doi:10.1038/nm.3730

939 Stefanik, M.T., Moussawi, K., Kupchik, Y.M., Smith, K.C., Miller, R.L., Huff, M.L., Deisseroth, K., Kalivas,
940 P.W., Lalumiere, R.T., 2013. Optogenetic inhibition of cocaine seeking in rats. *Addict. Biol.* 18,
941 50–53. doi:10.1111/j.1369-1600.2012.00479.x

942 Studer, M., McNaughton, P.A., 2010. Modulation of single-channel properties of TRPV1 by
943 phosphorylation. *J. Physiol.* 588, 3743–56.

944 Tye, K.M., Prakash, R., Kim, S.-Y., Fenno, L.E., Grosenick, L., Zarabi, H., Thompson, K.R., Gradinaru, V.,
945 Ramakrishnan, C., Deisseroth, K., 2011. Amygdala circuitry mediating reversible and
946 bidirectional control of anxiety. *Nature* 471, 358–362. doi:10.1038/nature09820

947 Urban, D.J., Roth, B.L., 2015. DREADDs (Designer Receptors Exclusively Activated by Designer
948 Drugs): Chemogenetic Tools with Therapeutic Utility. *Annu. Rev. Pharmacol. Toxicol.* 55, 399–
949 417. doi:10.1146/annurev-pharmtox-010814-124803

950 Walsh, V., Cowey, A., 2000. Transcranial magnetic stimulation and cognitive neuroscience. *Nat. Rev.*
951 *Neurosci.* 1, 73–9. doi:10.1039/b817729p

952 Wheeler, M.A., Smith, C.J., Ottolini, M., Barker, B.S., Purohit, A.M., Grippo, R.M., Gaykema, R.P., Spano,
953 A.J., Beenhakker, M.P., Kucenas, S., Patel, M.K., Deppmann, C.D., Guler, A.D., 2016. Genetically
954 targeted magnetic control of the nervous system. *Nat Neurosci* 19, 756–761.
955 doi:10.1038/nn.4265

956 Yaksi, E., Friedrich, R.W., 2006. Reconstruction of firing rate changes across neuronal populations
957 by temporally deconvolved Ca²⁺ imaging. *Nat. Methods* 3, 377–383. doi:10.1038/nmeth874

958 Young, J.H., Wang, M.-T., Brezovich, I.A., 1980. Frequency/depth-penetration considerations in
959 hyperthermia by magnetically induced currents. *Electron. Lett.* 16, 358–359.

960 Zhang, Q., Castellanos-rubio, I., Munshi, R., Orue, I., Pelaz, B., Gries, K.I., Parak, W.J., Pino, P., Pralle, A.,
961 2015. Model Driven Optimization of Magnetic Anisotropy of Exchange-coupled Core-Shell
962 Ferrite Nanoparticles for Maximal Hysteretic Loss. doi:10.1021/acs.chemmater.5b03261

963 Zhang, S., Gao, H., Bao, G., 2015. Physical Principles of Nanoparticle Cellular Endocytosis. *ACS Nano.*

964 Zhu, Y., Wienecke, C.F.R., Nachtrab, G., Chen, X., 2016. A thalamic input to the nucleus accumbens
965 mediates opiate dependence. *Nature* 530, 219–222. doi:10.1038/nature16954

966

967

968 **Figure Legends**

969 **Figure 1.**

970 **Figure 1.** Magnetothermal genetic neurostimulation activates TRPV1 channels by
971 heating membrane-bound magnetic nanoparticles using an alternating magnetic field

972 (A) Magnetic nanoparticles (MNPs) (brown), encapsulated in PMA polymer (blue
973 ring) are functionalized with NeutrAvidin (green), conjugated with DyLight550
974 fluorophores (red stars), and attached to the neuronal membrane via biotinylated
975 antibodies targeting membrane proteins. The neurons are transfected to express
976 temperature sensitive TRVP1 channels and the calcium indicator GCaMP6f.

977 (B) Applying an alternating magnetic field ('AMF on') heats the membrane bound
978 MNPs. This heat dissipates, raising the temperature locally near the membrane,
979 which activates the TRPV1 channels. The resulting calcium influx depolarizes the
980 neurons and is measured as a transient intensity increase of the GCaMP6f
981 fluorescence.

982 (C) The experimental setup combining the alternating magnetic field (AMF)
983 application with fluorescence microscopy for in-vitro studies. The AMF (dotted
984 lines) is produced by a five turn, continuously water cooled coil made of copper
985 pipe. The coil and capacitor C form an electrical resonator that is driven by a 7.5
986 kW alternating power source. Neurons grown on cover glass are placed directly
987 underneath the coil in a non-metallic sample holder. The AMF causes eddy
988 currents in metal parts, including the microscope objective (OBJ). Any focus drifts
989 are compensated by a fast laser autofocus (AF) (also see figure supplement 1).
990 Components within the red, dashed box are to scale.

991 (D) Transmission electron micrographs showing 12.5 ± 1.2 nm core-shell MNPs.
992 (Left) MNPs as synthesized. (Right) Negative staining visualizes the PMA
993 polymer shell encapsulating the dark inorganic nanoparticles. Scale bar is 100
994 nm long.

995 (E) From left to right: fluorescence micrographs of GCaMP6f⁺ (green) neuron;
996 labeled with MNPs (red); overlay of the GCaMP6f (green) and MNP (red) signals;
997 and transmitted light image of the same neurons. Scale bar 10 μ m (See also
998 figure supplement 2A).

999 (F) (Top) Local heating of MNPs during AMF application measured as a dip in
1000 DyLight 550 fluorescence intensity (red trace), which drops linearly with
1001 increasing temperature. The grey bar indicates the application of the AMF (22.4
1002 kA/m, 412.5 kHz). (Middle) Temperature change near MNPs, as calculated from

1003 the fluorescence data using the calibration shown in Figure S1C (black trace).
1004 (Bottom) The GCaMP6f fluorescence signal recorded in the neuron decorated
1005 with nanoparticles shows a Calcium transient after 5 s of AMF when the
1006 membrane temperature increased by 2 °C. Temperature decreased after the
1007 AMF was removed and the Calcium transients slowly subsided again.

1008

1009 **Figure 1 - figure supplement 1.** Imaging set-up compatible with AMF heating
1010

1011 Schematic of the autofocus setup, compensating any optical aberrations and z-shift
1012 caused by eddy current heating of the objective lens. The microscope objective
1013 (OBJ) was mounted on an adapter, controlled by piezo-electric z positioning system
1014 (PZT). The piezo-electric crystal was powered (-30V – 130V) by a supply unit (PU)
1015 which was controlled by the feedback system (FB). The feedback system adjusted
1016 the piezo power in accordance with the transduced signal from the laser unit (LAS),
1017 which monitored the relative position of the glass coverslip with respect to the
1018 objective lens.

1019

1020 Faux color micrograph showing a group of HEK293T cells showing in the same dish
1021 various control and experimental conditions. Cells co-transfected with (i) GCaMP6f
1022 only; (ii) GCaMP6f + AP-CFP-TM; (iii) GCaMP6f + TRPV1; (iv) GCaMP6f + TRPV1 +
1023 AP-CFP-TM were cultured in the same dish. The field of view contains cells with all
1024 four transfection conditions. MNPs only bound to the membrane (via biotinylated
1025 antibodies) of the AP-CFP-TM cells (conditions, ii and iv). Thus, we could obtain all
1026 the conditions, e.g. a) TRPV1⁺/MNP⁺; b) TRPV1⁻/MNP⁺; c) TRPV1⁺/MNP⁻ in the
1027 same field of view. Representative cells are marked in the micrograph. Top left
1028 shows the fluorescence micrographs taken through the GFP channel. All cells
1029 expressing GCaMP6f are visible here. Top right shows TRPV1 expression via the
1030 fluorescence of DsRed markers, in the same field of view. MNP fluorescence is
1031 shown through Alexa 647 channel (bottom left). Overlay of all three channels is
1032 shown in bottom right.

1033

1034

1035 **Figure 1 - figure supplement 2.** Control experiments in HEK293T cells
1036

1037 (A) Faux color micrograph showing a group of HEK293T cells showing in the same
1038 dish various control and experimental conditions. Cells co-transfected with (i)
1039 GCaMP6f only; (ii) GCaMP6f + AP-CFP-TM; (iii) GCaMP6f + TRPV1; (iv)
1040 GCaMP6f + TRPV1 + AP-CFP-TM were cultured in the same dish. The field of
1041 view contains cells with all four transfection conditions. MNPs only bound to the
1042 membrane (via biotinylated antibodies) of the AP-CFP-TM cells (conditions, ii and
1043 iv). Thus, we could obtain all the conditions, e.g. a) TRPV1⁺/MNP⁺; b) TRPV1⁻

1044 /MNP⁺; c) TRPV1⁺/MNP⁻ in the same field of view. Representative cells are
1045 marked in the micrograph. Top left shows the fluorescence micrographs taken
1046 through the GFP channel. All cells expressing GCaMP6f are visible here. Top
1047 right shows TRPV1 expression via the fluorescence of DsRed markers, in the
1048 same field of view. MNP fluorescence is shown through Alexa 647 channel
1049 (bottom left). Overlay of all three channels is shown in bottom right.

1050 (B) GCaMP6f signal change recorded from the culture (snapped in B). Only a)
1051 TRPV1⁺/MNP⁺ cells show Calcium influx with AMF application (grey bar; 22.4
1052 kA/m, 412.5 kHz). Conditions b) TRPV1⁻/MNP⁺; c) TRPV1⁺/MNP⁻ showed no
1053 change in baseline GCaMP6f fluorescence intensity. This shows that
1054 TRPV1⁺/MNP⁺ is the necessary and sufficient condition to evoke calcium influx
1055 with AMF.

1056
1057

1058 **Figure 1 - figure supplement 3.** Calibration for in-situ temperature measurements

1059
1060 Calibration of the temperature dependence of the fluorescence intensity of DyLight
1061 550. A suspension of MNPs coated with NeutrAvidin - DyLight 550 was slowly
1062 heated to 44 °C, while recording the fluorescence intensity. At each temperature
1063 point multiple measurements were taken, which were then averaged and the s.e.m
1064 calculated.

1065

1066 **Figure 1 - figure supplement 4.** Magnetic properties of nanoparticles and ferritin

1067 (A) Magnetization as function of external field at 37 °C per particle, comparing horse
1068 spleen ferritin (Data credit in Supplemental Methods section) to the exchange
1069 coupled core-shell MNPs used in our work. The magnetization per particle for
1070 ferritin is considerably smaller than that of the synthesized particles.

1071 (B) Magnetic dipole-dipole interaction energy as function of center-center separation
1072 between two MNP, comparing horse spleen ferritin (HoSF) particles to core-shell
1073 (Cobalt Ferrite/ Manganese Ferrite) particles. Magnetization per particle was
1074 calculated using the indicated magnetic field strengths at 37°C. The lower bound
1075 of x axis for each particle type coincides with the minimum distance of
1076 separation, when neighboring particles physically touch each other. As is evident,
1077 the interaction energy between ferritin particles are 6 - 7 orders lower than the
1078 thermal energy.

1079 (C) Comparison of SLPs of core-shell MNPs and horse spleen ferritin particles at
1080 various frequencies. The magnetic field strength chosen are obtained from the
1081 limiting cases of biomedical applications, at these frequencies. 5 log units lower
1082 SLP values are seen at frequencies under 1 MHz.

1083 **Figure 2.**

1084 **Figure 2.** Membrane bound MNPs heat the membrane locally without bath heating, cool
1085 quickly to turn signal off, and can heat more efficiently than MNP suspensions

1086 (A) Illustration showing MNP suspension in the bath above cells. During the AMF
1087 application the MNPs heated, raising the temperature of the entire bath volume,
1088 as measured by the fiber optic thermometer. The entire left column of this figure
1089 focuses on heating of a MNP suspension, while the right column compares this
1090 to heating the same MNPs when membrane bound. Not to scale.

1091 (B) Illustration showing MNPs bound via antibodies to the cell membrane. MNPs
1092 form a 2-dimensional sheet along the contour of the cell membrane. AMF
1093 nanoparticle heating is limited only to the immediate vicinity of the cell
1094 membrane. DyLight fluorophores were attached to the MNPs (orange MNPs) to
1095 measure the local temperature changes near the membrane bound MNPs via
1096 fluorescence microscopy. The bath temperature was monitored using the optic
1097 fiber thermometer. Not to scale.

1098 (C) Temperature rise and subsequent cooling during a 7 s AMF (22.4 kA/m at 412.5
1099 kHz) application in a MNP suspension (10 mg/ml) above the cells (blue).

1100 (D) Temperature rise and subsequent cooling during a 7 s AMF (22.4 kA/m at 412.5
1101 kHz) application on cell membrane bound MNPs (orange solid, recorded via
1102 fluorescence). Simultaneous recording of the bath temperature ((no perfusion,
1103 orange dashed line) confirmed that the MNP heating remains confined near the
1104 cell membrane. This is unlike the suspension heating of MNPs, where the entire
1105 bath heats uniformly. Another contrasting feature of membrane bound MNP
1106 heating seen here is the rapid cooling.

1107 (E) Temperature rise in suspensions of $\text{CoFe}_2\text{O}_4 - \text{MnFe}_2\text{O}_4$ core-shell MNPs at
1108 various concentrations plotted versus time. Numbers to the right indicate MNP
1109 concentration in mg/ml (AMF in all cases 22.4 kA/m at 412.5 kHz)

1110 (F) Heating rates of bound MNPs are dependent on the area density on the
1111 membrane. Temperatures recorded at various time points are linearly fitted
1112 (dashed lines). Blue markers indicate data collected from neurons, using
1113 biotinylated anti-A2B5 for particle binding. Red markers indicate data collected
1114 from HEK293T cells with MNP attached to enzymatically biotinylated surface
1115 proteins. Error bars incorporate measurement errors and error associated with
1116 temperature calibration from fluorescence measurement. (see also Figure 1C)

1117 (G) Rate of temperature rise plotted as a function of density of MNPs in suspension.
1118 Error bars indicate error in estimation of concentration. Y errors are smaller than
1119 the marker size. Dashed line shows the linear fit.

1120 (H) Temperature rise around MNPs bound to cell membranes plotted against the
1121 mean area density of the MNP distribution. X error bars indicate the error in
1122 estimation of MNP density and Y errors are obtained as mentioned in (F).

1123 (I) Stacked sheets of isotropically distributed nanoparticles. Scale bar is 100 nm
1124 long. The nanoparticle density shown, corresponds to that required for 0.5 °C/s
1125 rise in suspension temperature.

1126 (J) Individual sheets from (I). Same scale. The density is enough to heat the
1127 membrane by 0.5 °C/s.

1128

1129

1130 **Figure 2 - figure supplement 1.** Effect of AMF strength on local heating.

1131 Local temperature increase on HEK cells decorated with MNPs for two different AMF
1132 field strengths and durations: *Black* = low AMF (12 kA/m, 412kHz), 30s duration;
1133 Red = high AMF (30 kA/m, 412kHz), 5s duration; (sem shown as shading, n = 3).
1134 Note the asymptotic nature of temperature evolution in the low AMF case: as the
1135 rate of heat dissipation to the bath approaches that of heat generation rate of the
1136 MNPs, the rate of temperature increase decreases. Still, in both cases, the
1137 membrane is heated by more than 2 °C.

1138

1139 **Figure 3.**

1140 **Figure 3.** Within seconds of AMF application, membrane targeted MNP stimulate
1141 magnetothermally TRPV1⁺ neurons in culture

1142 (A) Rate of Action Potential firing as a function of bath temperature, recorded from
1143 GCaMP6f transients observed in TRPV1 expressing hippocampal neurons (red)
1144 and wild-type neurons (control, black) when perfused with pre-heated buffer. The
1145 Ca²⁺ transients are modeled by a spike train (see figure supplement 1). The data
1146 points are fitted with Hill equation, giving a midpoint of 37.7 ± 0.06 °C, which
1147 corresponds to half maximal firing rate (dashed curve).

1148 (B) GCaMP6f fluorescence intensity changes (green, Ca²⁺) in different TRPV1+
1149 neurons decorated with MNP (5s field, 22.4 kA/m at 412.5 kHz, in gray).
1150 Calculated spike events (black) are indicated under each Ca²⁺ trace (see figure
1151 supplement 2).

1152 (C) Change of cell surface temperature as measured by DyLight550 fluorescence
1153 (average of 3 experiments)

1154 (D) GCaMP6f signal recorded from nanoparticle coated TRPV1+ neurons binned in
1155 5s intervals, indicated by x error bar (mean \pm s.e.m, 13 neurons). The spiking
1156 frequency increased from 1.8 ± 0.6 per 5s, before AMF (field 0 to 5 s), to $4.5 \pm$
1157 1.2 per 5s, during the AMF ($n = 13$, ** $p = 0.0028$, unpaired T-test), and $12.1 \pm$
1158 2.0 per 5s immediately following the AMF ($n = 13$, *** $p = 0.0002$, unpaired T-
1159 test, 95% confidence intervals [1.5,2.23] and [10.8,13.3]) (Supplement 2).

1160 (E) Plot of activation latency, time interval between onset of field stimulation and first
1161 AP detect versus field duration. All data points lying on the gray background
1162 indicate that the first spike was detected while the field was still on (87% of
1163 events, $n = 79$, 6 cultures). Error bars indicate the temporal measurement
1164 uncertainty.

1165 (F) Percentage of neurons firing their first AP after field onset in the time interval
1166 indicated (subset of 41 cells from A which were stimulated for 5 s). The
1167 histogram was fitted (no weighting) with a Poisson curve ($\lambda = 2.18 \pm 0.17$ s).
1168 Error bars are obtained as difference in population between bins shifted to left
1169 and right, following temporal uncertainty as indicated in (E).

1170 (G) Percentage of active neurons in each time interval (Alternating magnetic field
1171 applied 0 - 5 s). Error bars: x indicate 5 s time bin, y as in (F). A five-second AMF
1172 application increased the active population from 53.7 ± 1.6 % to 80.5 ± 5.1 % of
1173 neurons, * $p = 0.032$, unpaired T-test, ($n = 41$, same as in (F)).

1174 **Figure 3 - figure supplement 1.** Procedure and controls to deduce spike train from
1175 GCaMP signal

1176 (A) Fluorescence micrographs of a GCaMP6f expressing neuron. (Left to right) raw
1177 image, as recorded; background subtracted with 50 pixel rolling ball on the same
1178 ROI; image after turning grey values of all pixels under a particular threshold
1179 intensity value to Not a Number (NaN). This operation removes noise and
1180 extracts pixels corresponding to soma for each frame of a video.

1181 (B) Mean and sem of Calcium peaks corresponding to single action potential events
1182 (see Supplemental Methods), recorded from 5 somas of WT rat hippocampal
1183 neurons expressing GCaMP6f. Data from each soma is the mean of 3 smallest
1184 calcium transients (kernel function). The average rise time is 232.2 ms and the
1185 $t_{1/2}$ of decay is 335.5 ms. The peaks resulted from spontaneous firing and were
1186 recorded over a temperature range of 32 – 40 °C. Black dashed curve shows
1187 exponential fits corresponding to the rise and fall phases.

1188 (C) Mean and sem of Calcium peaks corresponding to single action potential events,
1189 recorded from 6 somas of rat hippocampal neurons expressing GCaMP6f and
1190 TRPV1 channels. Data from each soma is the mean of 3 smallest calcium
1191 transients (kernel function) (recorded over 32 – 39 °C). The average rise time is
1192 220.0 ms and the $t_{1/2}$ of decay is 320.2 ms, showing no significant deviation from
1193 the peaks resulting from spontaneous firing. Black dashed curve shows
1194 exponential fits corresponding to the rise and fall phases.

1195 (D) Analysis of time course GCaMP6f fluorescence intensity change from the soma
1196 of a WT rat hippocampal neuron. (Top) Time course recording of GCaMP6f signal
1197 from the same soma (red) after exponential bleach correction. Overlaid in black
1198 is the reconstructed signal obtained by convolving the kernel function with binary
1199 action potential events. (Middle) Calculated action potentials (black sticks).
1200 (Bottom) Residual between the reconstructed waveform and the normalized
1201 signal is shown in blue. The scale indicates percentage change with respect to
1202 the signal baseline.

1203 (E) Analysis of time course GCaMP6f fluorescence intensity change from the soma
1204 of a rat hippocampal neuron expressing TRPV1 channels and decorated with
1205 nanoparticles on the membrane. (Top) Time course recording of GCaMP6f signal
1206 from the same soma (red) after exponential bleach correction. Overlaid in black
1207 is the reconstructed signal obtained by convolving the kernel function with binary
1208 action potential events. An increased firing rate is observed during AMF
1209 application (Grey bar) (Middle) Calculated action potentials (black sticks).
1210 (Bottom) Residual between the reconstructed waveform and the normalized
1211 signal is shown in blue. The scale indicates percentage change with respect to
1212 the signal baselin

1213 **Figure 3 – figure supplement 2**

1214 (A) Comparison of firing 5 second before, 1.8 ± 0.6 APs, and after the field start, 12.1
1215 ± 2.0 APs ($p = 0.0002$, $n = 13$).

1216 (B) Difference in the firing rate during the 5 second period before and the same
1217 period after field application, average 10.2 ± 2.1 APs ($p = 0.0004$, $n = 13$).

1218

1219

1220

1221 **Figure 4.**

1222 **Figure 4.** Magnetothermal neurostimulation in the motor cortex elicits fast scurries
1223 around the arena

1224 (A) Experimental set-up for in-vivo magnetothermal stimulation of motor behavior in
1225 awake mice. A water-cooled 2-turn coil around the arena generated the AMF. The
1226 AMF in the coil was powered by the same system as for the in-vitro experiments.
1227 An overhead camera was used to record the mouse's behavior in the arena.

1228 (B) Photograph of mouse in the observation arena; 2-turn water-cooled coil visible as
1229 black ring.

1230 (C) Representative trajectory recorded from a mouse stimulated in the motor cortex
1231 before (black), during (red), and after (blue) field application (each one minute
1232 long). The black circular border denotes the actual boundary of the chamber. (Also
1233 see figure supplement 2 for injection locations; and Video 1, 2, 6)

1234 (D) (Top) Position of the mouse's head, (x green; y orange) measured taking the
1235 center of the arena to be the origin. (Middle) Black trace shows the linear speeds
1236 of the mouse. Speed markedly increases during all AMF applications (Grey bars).
1237 After each AMF application, the mouse slows down regular exploratory motion
1238 (Bottom). Total turns made by the mouse was tracked versus time. Counter-
1239 clockwise angular changes were counted as a positive change in angles. During
1240 AMF application, the mouse turned unilaterally significantly more than between the
1241 AMF applications.

1242 (E) Comparison of linear speed of this TRPV1⁺ / MNP⁺ mouse, injected in the motor
1243 cortex, with and without AMF. The average linear speed increased 16-fold after
1244 AMF application, from 5.3 ± 2.75 mm/s, before AMF, to 83.8 ± 3.75 mm/s, during
1245 AMF (one mouse, four trials, the error bars are smaller than the symbols; $p =$
1246 $5.9 \cdot 10^{-6}$, 95% confidence intervals [0.9, 9.7] and [77.8, 89.8] mm/s).

1247 (F) Comparison of the angular speed from the same mouse as in (E). The angular
1248 speed during the AMF was 3.27 ± 0.30 rev/min versus 0.21 ± 0.19 rev/min between

- 1249 the AMF applications (one mouse, four trials, error bars are smaller than symbols;
 1250 $p = 0.0003$, 95% confidence intervals [-0.10, 0.53] and [2.78, 3.74] rev/min).
- 1251 (G) Comparison of angular velocity, or speed of circling the arena, measured for all
 1252 TRPV1⁺ / MNP⁺ mice, injected in the motor cortex, with or without AMF. The speed
 1253 of circling the arena in revolutions per minute increased 8-fold with AMF, from to
 1254 0.34 ± 0.08 rev/min to 2.81 ± 0.20 rev/min (6 mice, 14 trials; $p = 5.2 \cdot 10^{-9}$; 95%
 1255 confidence intervals [0.29, 0.39] and [2.69, 2.93] rev/min).
- 1256 (H) Latency of behavioral response onset and end after turning field on and off,
 1257 respectively (n = 21).
- 1258 (I) Speed of rotation for control and experiment animals (independent mice): *Control1*:
 1259 PBS instead of MNP injected (TRPV1⁺ / MNP⁻, n = 4); *Control2*: PBS instead of
 1260 virus injected (TRPV1⁻ / MNP⁺, n = 4); and *Experiment* (TRPV1⁺ / MNP⁺). There
 1261 was no significant difference in the observed speeds with or without AMF (AMF⁺
 1262 and AMF⁻, respectively) in the control cases. With TRPV1⁺ / MNP⁺, the mice
 1263 exhibited a highly significant increase in speed with AMF, 3.17 ± 0.17 rev/min, as
 1264 compared to the mice without AMF application, 0.42 ± 0.07 rev/min (n = 10, $p =$
 1265 $1.1 \cdot 10^{-5}$; unpaired T-test; 95% confidence intervals [0.32, 0.52] and [2.94, 3.40]
 1266 rev/min). In the experiments and controls 1 and 2 and MNP were injected with
 1267 A2B5 antibody (AB). *Control3*: MNP without antibody injected (TRPV1⁺ / MNP⁺,
 1268 AB⁻, n = 3).

1270 **Figure 4 - figure supplement 1.** Virus induced TRPV1 over-expression and membrane
 1271 bound MNP labeling of neurons in the Motor Cortex

- 1272 (A) Laser confocal image of soma and dendrites of neurons labeled by anti-
 1273 microtubule-associated-protein (MAP2) antibody.
- 1274 (B) Anti-TRPV1 antibody shown TRPV1 expression on the membrane. Same ROI as
 1275 A. TRPV1 overexpression was achieved through AAV5-hSyn-TRPV1 viral
 1276 infection.
- 1277 (C) MNPs labeling membrane of neurons in the motor cortex. Same ROI as in panel
 1278 A. The MNPs were co-injected with A2B5 antibodies.
- 1279 (D) Overlay of the panels MAP2 (green), anti-TRPV1 (red) and MNP (blue).

1281

- 1282 **Figure 4 - figure supplement 2. (Top)** Angular displacement (negative CW, positive
 1283 CCW) of mice stimulated magnetothermally in the motor cortex (7 trials, 3 mice).
 1284 **(Bottom)** As the mice change direction during the runs we also plotted the total
 1285 angular distance travelled.

1286

1287 **Figure 4 - figure supplement 3.** Repeatability of stimulation in motor cortex

1288 The figure shows two sessions of trials performed on the same mouse over a course of
1289 2 days (12 hours and 36 hours post injection of MNPs). The animals position is
1290 recorded from the video and the cumulative angular distance travelled plotted. Four
1291 weeks earlier, the animal was injected with TRPV1⁺ and MNP⁺ (with AB) in the motor
1292 cortex.

1293

1294 **Figure 4 - figure supplement 4.** An example for a mouse injected with virus and MNPs
1295 but without the anti-A2B5 antibody. These animals do not respond to the AMF
1296 application.

1297

1298 **Figure 4 - figure supplement 5.** Magnetic field distribution across experimental arena

1299 Root-mean square magnetic field strengths were measured by a Fluxtrol alternating
1300 field probe. The plot shows the magnetic field profile of a 100 mm diameter 2 turn coil
1301 resonating at 570 kHz. Measurements were done along a coil diameter, lying on a
1302 plane midway between the two turns. The error bars show bounds of variation in field
1303 strength over cycles. All in-vivo stimulations were carried out in a circular arena
1304 bounded by the coil.

1305

1306

1307

1308

1309

1310 **Figure 5.**

1311 **Figure 5.** Magnetothermal neurostimulation in the striatum elicits rapid rotations
1312 around body axis

1313 (A) Trajectory of a representative TRPV1⁺ / MNP⁺ mouse, injected in the striatum,
1314 during AMF application (1 minute long). The mouse remained near the center of
1315 the arena, as it turned unilaterally around its body axis (in contrast with the motor
1316 cortex injected mouse). Black circle represents the actual arena boundary.

- 1317 (B) Two one-minute trajectories of the same mouse without AMF (black: before AMF
 1318 application, blue: after AMF application). The mouse carried out regular
 1319 resting/exploratory activities, turning 5 times less than that with AMF (Also see
 1320 Video 3, 6)
- 1321 (C) (Top) Trajectory (x,y positions, x green; y orange) of the mouse shown in part (A)
 1322 and in Video 3. One minute long AMF was applied twice (gray bar). (Middle)
 1323 Linear speed in mm/s of the same mouse calculated from the trajectory. (Bottom)
 1324 Plot of the angular displacement, in revolutions, calculated from the trajectory.
 1325 The mouse turns unilaterally counterclockwise (to the left) during the AMF
 1326 applications.
- 1327 (D), (E) Comparison between linear and angular speeds of the same mouse with
 1328 (red) and without (blue) AMF.
- 1329 (F) Records of 12 stimulation trials in 4 mice. The motion is tracked and the angular
 1330 displacement recorded (negative angular displacement is CW, while positive is
 1331 CCW). In AMF application, the mouse only turns in one direction, typically for 3 to
 1332 4 turns, and in 11 out of 12 cases it turns contra-lateral to the injected brain half.
 1333
- 1334 (G) Comparison of angular velocity, or turning speed, in revolutions per minute
 1335 measured for all TRPV1+ / MNP+ mice, injected in the striatum: angular speed
 1336 during AMF, 3.46 ± 1.04 rev/min, was 5.8-fold the angular speed without AMF,
 1337 0.37 ± 0.22 rev/min (4 mice, 12 trials, $p = 3.74 \cdot 10^{-7}$; unpaired T-test; 95%
 1338 confidence intervals [0.33, 0.41] and [3.27, 3.65] rev/min, mean \pm s.d.).
 1339

1340

1341

1342 **Figure 5 - figure supplement 1.** Repeatability of stimulation in striatum

1343 The figure shows three sessions of trials performed on the same mouse over a course
 1344 of 2.5 days (time points are indicated above each plot, gray shaded areas are the AMF
 1345 applications). The animal was injected with TRPV1⁺ and MNP⁺ (with AB) in the striatum.

1346

1347

1348 **Figure 5 - figure supplement 2.** Confirmation of targeted region in the Striatum

1349 (A) MNPs covered cells in the target volume in the striatum seen through Alexa 647
 1350 attached to the MNPs. (Dashed lines are added for visual anatomical guidance)

1351 (B) MNPs (re

1352 (C) overlaid on transmitted light image of the brain section.

1353

1354 **Figure 5 - figure supplement 3.** Co-localization of virus induced channel expression
1355 and MNP binding in the striatum.

1356 (A) Immunostaining TRPV1 expressing cells, infected with AAV5-hSyn-TRPV1. The
1357 TRPV1 is labeled using anti-TRPV1 antibody (Abcam) with secondary antibody.

1358 (B) MNPs tagged with fluorescent marker (Alexa 647), injected in the same location
1359 4 weeks after the virus injection.

1360 (C) An Overlay of TRPV1 expression (green), MNPs (red) and the transmitted light
1361 image (grayscale).

1362

1363 **Figure 5 - figure supplement 4.** Virus induced TRPV1 over-expression in the Striatum

1364 (A) Laser confocal image of soma and dendrites of neurons labeled by anti
1365 microtubule-associated-protein (MAP2) antibody.

1366 (B) TRPV1 overexpressed through AAV5-hsyn-TRPV1 viral infection, visualized using anti-
1367 TRPV1 antibody (Abcam) with Alexa-647 tagged secondary antibody.

1368 (C) Overlay of MAP2 (green) and TRPV1 (red) labels.

1369 (A) Lentivirus induced TRPV1 overexpressing cells in striatum visualized by imaging the
1370 NLS-mCherry nuclear marker encoded in the lentivirus.

1371 (B) Overlay of the NLS-mCherry (viral infection marker, green) and a transmitted light image
1372 (gray scale).

1373

1374 **Figure 5 - figure supplement 5.** Antibody assisted targeting confines MNP spread

1375 (A) Fluorescence micrographs, showing MNP spread around the delivery location,
1376 when introduced with (i) and without (ii) A2B5 antibodies. Alexa 647 tagged MNP
1377 are visualized as red stains in both cases. Relative fluorescence is not
1378 normalized for (i) and (ii).

1379

1380 (B) Fluorescence intensity plots comparing spread of MNPs around the delivery
1381 location, when introduced with (red) and without (black) A2B5 antibodies.
1382 Shading indicates SEM (3 brain sections from 3 animals). Spread FWHM was
1383 $106.0 \pm 0.8 \mu\text{m}$ and $251.3 \pm 4.8 \mu\text{m}$ for the with and without A2B5 antibody
1384 cases, respectively.

1385

1386 **Figure 5 - figure supplement 6.** Antibody enhances membrane targeting of MNPs
1387 Four videos showing MNP labeling on cells, imaged as confocal sections at cellular
1388 resolution. In all cases green indicate MAP2 staining in the striatum, while MNP
1389 labeling is shown in red. In all cases MNP was co-delivered with A2B5 antibodies
1390 (1:1 particle: antibody molecule ratio). Left panel in each movie shows MNP labeling,
1391 while the right panel is an overlay of the same roi, showing MAP2 and MNP
1392 channels. Brain sections from two animals have been showcased here. Both
1393 animals were sacrificed and perfusion fixed, 24 hours after the MNP delivery
1394 procedure. Associated video-animations:

- 1395 • Figure 5 -Video 1 – Related to Figure 5-figure supplement 6. Cellular resolution
1396 confocal z-sections of MNP with anti-A2B5 antibodies binding neurons in the
1397 brain. (example 1)
- 1398 • Figure 5 - Video 2 – Related to Figure 5-figure supplement 6. Cellular resolution
1399 confocal z-sections of MNP with anti-A2B5 antibodies binding neurons in the
1400 brain. (example 2)
- 1401 • Figure 5 - Video 3 – Related to Figure 5-figure supplement 6. Cellular resolution
1402 confocal z-sections of MNP with anti-A2B5 antibodies binding neurons in the
1403 brain. (example 3)
- 1404 • Figure 5 - Video 4 – Related to Figure 5-figure supplement 6. Cellular resolution
1405 confocal z-sections of MNP with anti-A2B5 antibodies binding neurons in the
1406 brain. (example 4)

1407

1408

1409

1410 **Figure 5 - figure supplement 7.** Neuronal cells health after multiple AMF exposures

1411 Histology of MNPs decorated neurons after the awake, behaving animal was exposed
1412 to 20-times one-minute AMFs applications over the course of 3 sessions over a 24
1413 hours period.

1414 (A) Neurons labeled using anti-MAP2 antibody.

1415 (B) MNPs labeled by attached Alexa-647 dye.

1416 (C) Overlay of MAP2 (green) and MNPs (red).

1417

1418 **Figure 6.**

1419

1420 **Figure 6.** Magnetothermal stimulation near the ridge between ventral and dorsal
1421 striatum caused freezing of gait (FOG)

- 1422 (A) Track of mouse stimulated in deep striatum before (black), during (red), and after
 1423 (blue) AMF application (each one minute (Also see figure supplement 2, Video 4,
 1424 5, and 6)
- 1425 (B) X,Y-position and linear speed of same animal tracked at the neck. The speed is
 1426 compared to a fixed reference point in the sample chamber (blue line; Grey bar
 1427 indicates the field duration).
- 1428 (C) Scatter plot, showing the response of two mice with AMF. The average speed
 1429 without AMF (17.7 ± 2.2 mm/s) was significantly faster than that with AMF ($1.04 \pm$
 1430 0.13 mm/s) (2 mice, 6 trials; $p = 0.0006$; unpaired T-test; 95% confidence
 1431 intervals [15.4, 20.1] and [0.90, 1.18] mm/s). The speed during AMF was very
 1432 similar to the speed of fixed reference marker (0.52 ± 0.11 mm/s).
- 1433 (D) Still picture of same before (top) and during (bottom) field. The red arrowheads
 1434 indicate paw position during stimulated freezing of gait (FOG). During the AMF
 1435 the mouse is able to move its head but not control the limbs which end up
 1436 stretching farther apart than normal and are unable to follow the head's motion.
 1437 In the absence of AMF, ambulation is normal and front paws are positioned to
 1438 both sides of the head position and hind paws underneath the animal's body.

1439

1440 **Figure 6 - figure supplement 1. Targeted Region in the Striatum**

1441 (A) Coronal Rostral to caudal section of the deep striatum where virus and then two
 1442 weeks later MNP were injected near the ridge between Dorsal and Ventral
 1443 striatum (AP = 0.01, ML = 2.3, DV = 4.1) (Red dot, all in mm).

1444 (B) Sagittal view.

1445

1446

1447 **Figure 6 - figure supplement 2. Paw Location Data for Freezing of Gait Response**

1448 (E) - (H) Paw Location Data for Freezing of Gait Response. Tracking data (X, blue;
 1449 Y, green) of the four paws, before, during, and after field application. The field is
 1450 applied from 0s to 60s. The red and black traces are the X, Y coordinates of a
 1451 fixed reference marker.

1452

1453

1454

1455

VIDEO LEGENDS

1456

1457 **Video 1 - Ambulatory response generated by secondary motor cortex stimulation.**
1458 Unilateral stimulation in the motor cortex evokes running with some delay. The
1459 ambulatory response persists during the 60 s long field application and the stimulation
1460 can be repeated within minutes. The video shows one continuous experiment with 4
1461 field, which each lead to a long run, typically 3-4 times around the arena. Video speed is
1462 3x accelerated, MNP injection and application of the field marked within the video
1463 frames.

1464

1465 **Video 2 - Control video of the same mouse without any field application.**

1466

1467 **Video 3 - Body-axis turning caused by local stimulation in the dorsal striatum.**

1468 The video shows the mouse's response to field, resulting from stimulation of striatum.
1469 The response is repeatable, as shown here in one continuous recording with two trials.
1470 The mouse makes two complete and uninterrupted ipsilateral turns during the first field
1471 application and one complete ipsi - and contra - lateral turn each during the second
1472 field. The turn radii are not limited by the arena boundary. Video playback speed 3X;
1473 injection site and field times are shown as overlays.

1474

1475 **Video 4 - Freezing of gait caused by local stimulation in the deep striatum.**







1476 The mouse was injected 4.1mm deep in the striatum, near the ridge between Dorsal
1477 and Ventral striatum. Upon field application, the limbs and tail of the mouse are
1478 rendered motionless, while the rest of the body, including the neck retains normal
1479 mobility. Sometime past the stimulation, the mouse regains control over the limbs and
1480 moves freely again. Video playback speed in 3X the recording speed. Injection site in
1481 the brain and field times are shown as overlays.


1482


1483 **Video 5 - Control video of Freezing of gait.**

1484 **Video 6 - Control video of a mouse injected with virus but not MNP.**


1485 **Video 7 - Control video of a mouse injected with MNP but no virus.**









B












Suspension











Membrane Bound






Temperature Change with AMF




A**B**







A





Action potential per 5 s



**B**



Difference in Action potential per 5
























A 12 hours**B** 36 hours


































A**B**






A


Left Front Paw

**B**

Right Front Paw

**C**

Left Hind Paw

**D**

Right Hind Paw

